Rare Genetic Variants in Nutrient Transporters: Impact on drug response and human disease by Enogieru, Osatohanmwen Jessica
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Rare Genetic Variants in Nutrient Transporters: Impact on drug response and human 
disease
Permalink
https://escholarship.org/uc/item/28q4m6hq
Author
Enogieru, Osatohanmwen Jessica
Publication Date
2020
Supplemental Material
https://escholarship.org/uc/item/28q4m6hq#supplemental
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
  
 
 
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 



"#&!$
!#!#"$#!#!" !#!"
 #!$!" "$
""
!$#"!"
	
	
#
%
%#$%
#
	 ii	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 iii	
Acknowledgements 
This dissertation is the culmination of almost 6 years of research that would not have reached 
fruition without the constant love, encouragement, guidance and support I have received from 
family, friends and colleagues. 
First, I would like to thank Dr. Kathleen Giacomini, my mentor and advisor, for her 
guidance and support. Kathy is a premier example of scientific expertise, rigor, leadership and 
creativity. I am quite fortunate to have spent my formative years as a scientist learning not only 
from her scientific expertise, but her professional expertise as a leader. Kathy’s mentorship style 
has encouraged my scientific growth, independence and creativity; skills that build the 
foundation for any career in science. Second, I would like to thank members of my dissertation 
committee Dr. Nadav Ahituv and Dr. Rada Savic, and members of the qualifying exam 
committee Dr. Pui Kwok, Dr. Deanna Kroetz, and Dr. Lisa Kroon for their important feedback 
and advice regarding my proposed research projects and dissertation. Third, I would like to 
acknowledge and thank Dr. SookWah Yee for her guidance, encouragement and significant 
contribution to my scientific development and technical expertise.  
Fourth, I would like to thank all members of the Giacomini lab, both past and present, who have 
contributed to my scientific development and education (Huan-Chieh Chien (James), Elizabeth 
Green, Ling Zou, Xiaomin Liang, Adrian Stecula, Shylaja Srinivasan, Deanna Brackman, Bianca 
Vora, Huy Ngo, Renata Gallagher) and making the Giacomini lab a welcoming learning 
environment. Fifth, I would like to thank Dr. Daniel L Minor for providing access to his lab and 
its equipment, which was critical in the execution of my research. 
	 iv	
Additionally, I would like to thank Chenling, Megan Li, Kat Zhua, (members of the Deanna 
Kroetz lab) and Fayad Abderemane-Ali and Lianne Pope (members of the Daniel Minor lab), for 
their encouragement, guidance and technical expertise.   
Additionally, I had the great honor of working with and learning from a variety of collaborators 
(Dr. Avner Schlessinger, Dr. Peter Ung, Dr. Chien-Yu Chen, Dr. Yu-Chuan Chang (Chester), Dr. 
Marina Sirota) during my graduate school experience, and this work would not have been 
accomplished without their incredible contributions and dedication.  
To all of my new friends (both UCSF and non-UCSF affliated) and old friends, I am incredibly 
grateful for your support. Without my community of friends and supporters, I would not have 
successfully completed my PhD program. Thank you for showing me the power and blessings of 
community, and for providing me with so many beautiful memories and experiences. 
And, to my family (Daddy, Mommy, Juanita, Imarhia and Idia), thank you for always believing 
in me and encouraging me to be my best. Thank you for being the ultimate source of peace, joy, 
rejuvenation and renewal during the best and hardest times of my life. You have been and 
continue to be my biggest source of inspiration. 
 
 
 
 
 
 
 
 
 
	 v	
Contributions 
 
Enogieru OJ, Ung PMU, Yee SW, Schlessinger A, Giacomini KM. Functional and structural 
analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits. 
Hum Mutat. 2019 Jul;40(7):983-995.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vi	
Rare Genetic Variants in Nutrient Transporters: Impact on drug response and human 
disease 
 
Osatohanmwen Jessica Enogieru 
 
Abstract 
 
Translational research, often referred to as “bench-to-bedside” science, involves converting 
novel biological, chemical or other scientific discoveries into clinically relevant medical 
treatments, devices and/or applications.  Reverse translational research uses basic science tools 
and experimental models to investigate the biological, physiological and molecular mechanisms 
behind observations in human clinical data. 
In this dissertation project, we use both approaches to investigate the influence of nutrient 
membrane transporters on clinical drug response and human disease.  
 
Metformin is first-line treatment for Type 2 Diabetes (T2D), a metabolic disorder characterized 
by excessive glycemia and reduced insulin production and sensitivity. The prevalence of Type 2 
Diabetes is growing both in the U.S. and globally. Therefore, a larger and increasingly diverse 
population of individuals will be treated with metformin. The heritability of metformin response 
is substantial (about 33%), but common genetic variants previously identified to associate with 
metformin response (SLC2A2, solute carrier family 2 member 2; ATM, ataxia telangiectasia 
mutated	serine/threonine kinase) do not fully account for all the heritability. Our translational 
approach starts with conducting a metformin sequencing association study in a cohort of patients 
who responded very well (extreme responders) or poorly (extreme non-responders) to metformin 
to identify rare variants in the glucose transporter, GLUT2 (SLC2A2) that modulate metformin 
response.  In this dissertation, I describe the study design and various data analytical approaches 
that will be used to discover rare variants in SLC2A2 that associate with metformin response.   
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In our reverse translational approach we focus on rare variants in the same gene (SLC2A2), 
which are causal for Fanconi-Bickel syndrome (FBS), an autosomal recessive glycogen storage 
disease.  Mild and severe forms of FBS have been observed and reported in the clinical literature, 
but the question of whether residual function of mutant GLUT2 associates with disease severity 
has not been examined. So, I functionally characterized the impact of GLUT2 mutations causal 
for FBS on both transporter function and membrane expression. In the study, I identified a 
variant (p.Leu153_Ile154del), found in patients with a mild form of FBS that retained residual 
glucose transport activity, suggesting that small increases in GLUT2 activity could substantially 
reduce the severity of FBS symptoms.  
 
In our final study I conducted a screen of prescription drugs as inhibitors of THTR-1 (thiamine 
transporter encoded by SLC19A2, solute carrier family 19 member 2). The results of that screen 
identified several prescription and one over-the-counter drugs that inhibit THTR-1. Using data 
from electronic medical records, we observed significantly reduced thiamine pyrophosphate 
levels in blood samples from patients exposed to two THTR-1 inhibitors (erythromycin, 
omeprazole) versus samples from age and sex- matched individuals not on the drugs, suggesting 
inhibition of THTR-1 in vivo.  Both drugs are associated with megaloblastic anemia, which is 
also caused by genetic mutations in THTR-1.  The results suggest the possibility of a novel 
mechanism for drug-induced megaloblastic anemia.  
Our overall findings of the dissertation have important implications for understanding the role of 
micro- and macro- nutrient transporters in drug response and human disease.  Our studies 
continue to examine the role of genetic variants in the glucose transporter gene, SLC2A2 and 
metformin response, extending the application of precision medicine to the pharmacological 
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treatment of T2D.  Importantly, our studies suggest novel treatment strategies for rare diseases 
caused by genetic mutations in nutrient transporter, like FBS, and novel mechanisms for drug-
induced disorders, such as drug-induced megaloblastic anemia. 
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Chapter 1: The role of SLC2A2 (GLUT2) in human disease and drug response 
 
INTRODUCTION 	
Transporters are integral membrane proteins that mediate the translocation of substrates across 
biological membranes. SLC (solute carrier) proteins are encoded by genes in a large superfamily, 
which are expressed in various biological membranes  (i.e. extracellular plasma membrane, 
intracellular organelle membranes) in cells.1 In humans, SLC transporters are responsible for the 
absorption, distribution and elimination of nutrients, vitamins and minerals required for the 
metabolic and physiological function of cells, tissues and the body as a whole1 as well as for 
exogenous compounds including prescription drugs and herbal medications.   
 
Glucose is a necessary nutrient for nearly all forms of life; glucose and other simple 
monosaccharides are used for critical functions such as energy production/storage (i.e. glucose, 
fructose) structural integrity (i.e. xylose) and genetic replication (i.e. ribose). However, because 
of their polar nature and large size, monosaccharides such as glucose poorly traverse biological 
membranes via passive diffusion.2 Within the SLC super-family, there are three eukaryotic 
glucose transporter sub-families that facilitate transport of glucose across biological membranes, 
which are named GLUTs (encoded by SLC2A genes), SGLTs (encoded by SLC5A genes) and 
SWEETs (encoded by SLC50A1, solute carrier family 50 member 1).3 GLUT transporters, with 
one exception (HMIT, a H+/myo-inositol symporter), are facilitative which means they do not 
use energy from ATP or a secondary source (electrolyte gradients) to translocate glucose across 
membranes; instead, they move their substrates across the membrane in accordance with the 
concentration gradient.4    
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In this introductory chapter, I present a brief overview of some of the transporters in the GLUT 
family, in particular, GLUT1, GLUT4 and GLUT2.  A large component of this dissertation 
focuses on GLUT2; therefore more introductory information on GLUT2 is included. This is 
followed by a brief overview of the micronutrient transporter, THTR1, encoded by SLC19A2.  
Following this overview section, I then present goals of my dissertation research and briefly 
describe the individual chapters.    
Overview of Glucose Transporters in the SLC2A Family 	
Two of the most widely studied glucose transporters are members of the GLUT family: GLUT1 
and GLUT4.  GLUT1, encoded by SLC2A1 (solute carrier family 2 member 1) and discovered in 
1985,5 has a high Michaelis-Menten constant for glucose (Km = 3 mM).6 The Michaelis-Menten 
constant (Km) is the concentration at which a transporter reaches 50% of its activity (i.e. rate of 
transport) and represents the affinity of a substrate towards a transporter. In general, GLUTs 
have high Michaelis-Menten constant (i.e. a low transport affinity for its substrate) that are in the 
millimolar range for glucose. But considering the average blood glucose concentration in 
humans is 5 mM, GLUT1 efficiently transports glucose even in fasted (3.9 – 5.5 mM) or 
hypoglycemic (< 3.9 mM) conditions. It is ubiquitously expressed throughout different human 
tissues, the most critical being tissues within the brain. During normal conditions, the brain is 
completely reliant on glucose as an energy source; glucose transport into the brain is the rate-
limiting step for brain glucose metabolism.4,6 GLUT1 is highly expressed on the luminal 
membrane of brain endothelial cells and in astrocytes.4 Homozygous knockdown of GLUT1 in 
mice leads to embryonic lethality. In humans, heterozygous knockdown of GLUT1 leads to 
autosomal dominant Mendelian disease called GLUT1 deficiency syndrome (GDS) that is 
characterized by seizures in early infancy, developmental delay, ataxia, and neurobehavioral 
	 3	
symptoms.4 Intronic variants in GLUT1 significantly associate with hematological traits (e.g. 
monocyte count). Interestingly, there are no published studies that report a genome-wide 
association between genetic variants in GLUT1 and a common disease or drug response 
phenotype7 consistent with high selective pressure on SLC2A1. 
 
GLUT4, encoded by SLC2A4 (solute carrier family 2 member 4) and discovered in 1988,8 also 
has a high Km for glucose (Km = 5 mM) and is mainly expressed in skeletal muscle cells, 
cardiomyocytes and adipocytes. GLUT4 functions as an insulin-responsive glucose transporter.  
At low insulin concentrations, GLUT4 resides primarily in intracellular membrane 
compartments. When insulin concentrations increase after a carbohydrate meal and interact with 
insulin receptors, intracellular GLUT4 transporters redistribute to the plasma membrane. The 
insulin-stimulated plasma membrane redistribution of GLUT4 results in increases in glucose 
uptake and metabolism in these tissues, preventing chronic elevations in blood glucose levels. 
Mice born without functional GLUT4 in any tissue develop cardiac hypertrophy, exhibit growth 
retardation and die prematurely.9 To date, there are no known human Mendelian diseases or 
syndromes linked specifically to GLUT4 deleterious variants.  Furthermore, variants in GLUT4 
significantly associate with blood pressure traits, but notably, there are no published studies that 
report a genome-wide association between GLUT4 variants and a common disease or drug 
response phenotype.7 
GLUT2’s physiological role 	
In contrast to the plethora of manuscripts focused on studies of GLUT1 and GLUT4, 
considerably fewer studies focus on GLUT2, the second glucose transporter in the GLUT 
subfamily. Compared with the other four major GLUT proteins, GLUT2 (encoded by SLC2A2, 
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solute carrier family 2 member 2) exhibits a unique substrate specificity and transporter kinetic 
characteristics that underlie its specific physiological roles. First characterized in 1988,8,10 human 
GLUT2 is mainly expressed in four cell types: hepatocytes, enterocytes, renal proximal tubule 
cells and pancreatic beta cells (Figure 1.1A).  In body tissues, GLUT2 expression is highest in 
the liver. It is the primary glucose transporter in the liver and is the rate-limiting step for glucose 
flux in and out of the liver (Figure 1.1B).  
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Figure 1.1 GLUT2 transporter tissue localization. 
Human GLUT2 is mainly expressed in four cell types: hepatocytes, enterocytes, renal proximal 
tubule cells and pancreatic beta cells (A). In hepatocytes, GLUT2 is responsible for the 
bidirectional transport of glucose in and out of the liver. The primary mechanism of action of 
biguanide compounds, like metformin, occurs in the liver and results in decreased glucose 
synthesis and glucose output into the bloodstream (B). In the pancreatic beta cells, GLUT2 acts 
as a glucose sensor. Inactivation of GLUT2 in pancreatic beta cells leads to a significant 
reduction in glucose-stimulated insulin secretion (C).  
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GLUT2 expression is second highest in the enterocytes of the small intestine. However, in the 
intestine, other glucose transporters, which have higher affinities (low Km) are also expressed 
(i.e. SGLT1 (encoded by SLC5A1, solute carrier family 5 member 1), GLUT1, GLUT3 (encoded 
by SLC2A3, solute carrier family 2 member 3)), GLUT2 is also expressed in the renal proximal 
tubule of the kidney, where is participates in glucose reabsorption in partnership with SGLT2 
(encoded by SLC5A2, solute carrier family 5 member 2).  GLUT2 is expressed in low but notable 
levels in pancreatic beta cells that are solely responsible for insulin synthesis. Studies that 
evaluated glucose-stimulated insulin secretion (GSIS) of islet cells in GLUT2 -/- mice found that 
the number of beta cells was decreased, gene transcription and mRNA translation of insulin was 
suppressed and GSIS was severely reduced (Figure 1.1C). Once GLUT2 cDNA was reintroduced 
back into GLUT2-null islet cells, GSIS was normalized.11,12,13 These studies suggest that GLUT2 
is not only a glucose transporter, but based on its unique kinetic parameters, is a glucose sensor 
and detector for specific tissues.     
 
Compared with other GLUT and non-GLUT glucose transporters, GLUT2 has the highest Km for 
glucose (Km = 17 mM, Table 1.1). GLUT2 is defined as a low affinity, high capacity glucose 
transporter that can transport large amounts of substrate during periods of high glucose 
concentrations (i.e. post-prandial carbohydrate ingestion).14, 15 Additionally, GLUT2 has a broad 
substrate range compared with other GLUTs. For example, GLUT2 is one of the few fructose 
transporters in the body. GLUT2 in the basolateral membrane of enterocytes works in concert 
with GLUT5 on the apical membrane to transport fructose (Km = 76 mM), a monosaccharide 
found primarily fruits and plants, into the bloodstream from the small intestine. 	
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Table 1.1 The affinity (Km) of glucose transporters for D-glucose.  
Glucose transporter Km 
GLUT1 3 mM 
GLUT2 17 mM 
GLUT3 1.4 mM* 
GLUT4 5 mM 
GLUT5 -- 
SGLT1 0.4 mM 
SGLT2 ≤ 6mM 
SGLT3 --  
(glucose sensor) 
SWEET1 Stimulates glucose efflux 
The Km of glucose for the main, human glucose transporters in each class of glucose transporters 
(GLUTs, SGLTs, SWEET1) is listed. * = Km only available for 2-deoxyglucose, not glucose. --  
= does not transport glucose 
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Figure 1.2 Chemical structures of GLUT2 substrates 
The structure of GLUT2 substrates has either a five-membered ring or a six-membered ring. 
GLUT2 substrates are monosaccharides that are hexoses (six carbon atoms) or pentoses (five 
carbon atoms). 
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Interestingly, GLUT2 has a lower Km for glucosamine (Km = 0.8 mM) and dehydroascorbic acid 
(Km = 2.33 mM) than glucose (17 mM) (Figure 1.2). In addition to GLUT2’s broad list of known 
substrates, I identified three novel substrates of human GLUT2, as described in Chapter 3 of this 
dissertation, which were previously unknown: ribose, 1,5 anhydroglucitol, and xylose.  
 
GLUT2’s unique affinity for glucose and its broad substrate range has been linked to its specific 
amino acid sequence in key regions of the protein. GLUT2’s amino acid sequence is only 39-
53% identical to the amino acid sequence of GLUTs 1-5, with GLUT1 having the highest 
percentage (53%) and GLUT5 having the lowest (39%).16 Several protein chimera studies have 
implicated trans membrane helix 7 as the region responsible for GLUT2’s high Km for glucose 
and its ability to transport fructose.17,18,19,20  
GLUT2’s role in disease genetics and drug response 	
Genome-wide association studies (GWAS) are a powerful and agnostic approach used to identify 
causal variants and genes that influence development of a phenotype like a  
disease or response to a drug. GWAS associate specific genetic variations with particular 
diseases by scanning the genomes from many different people and looking for genetic markers 
that can be used to predict the presence of a disease. Notably, GLUT2 has been implicated in 
more GWAS studies of common diseases (i.e. Type 2 Diabetes)21,22 and metabolic traits (i.e. 
fasting blood glucose, body mass index, serum cholesterol)23,24,25,26 then any other GLUT 
transporter.7 In addition to disease phenotypes, variants in SLC2A2 have also been associated 
with response to drugs, specifically response to the highly prescribed anti-diabetic drug, 
metformin (Figure 1.1B). In 2016, in collaboration with Ewan Pearson and others, our laboratory 
performed a large GWAS with replication (N = 10,298 from several cohorts) with the focus on 
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initial glycemic response to metformin.27 The GWAS, conducted initially in patients of European 
ancestry, identified a genome-wide level significant association between rs8192675 (C-allele) in 
the SLC2A2 gene (encodes for the GLUT2 transporter) and greater response to metformin (p = 
5.9x10-15). Also, rs8192675, a common variant with a minor allele frequency (MAF) of 30% in 
Europeans, significantly associated with increased metformin response in three other ethnic 
groups (African-Americans, Latinos, East Asians), though p values were weaker likely due to 
smaller sample sizes.28 Subsequently, a second independent study published in 2019 confirmed 
rs8192675 association with metformin response29 and collectively these studies provide strong 
support for a role of GLUT2 in initial glycemic response to metformin. Unfortunately, due to the 
inherent limitations of GWAS analysis, we do not know if or how rare (MAF < 5%) SLC2A2 
variants influence glycemic response to metformin.  
 
It is also known that rare, inactivating variants in SLC2A2 cause a Mendelian glycogen storage 
disease known as Fanconi-Bickel syndrome (FBS, OMIM# 227810; FBS disease characteristics 
are described in Chapter 3). Over 40 FBS variants have been identified, but the impact of these 
variants on GLUT2 transporter function, expression and FBS phenotype were rarely, if ever, 
studied.30 Unfortunately, this is a common issue with Mendelian diseases caused by a SLC 
transporter, with a few exceptions (i.e. Carnitine Transporter Deficiency syndrome). The lack of 
functional studies likely contributes to the unavailability of FDA-approved drugs for genetic 
diseases caused by SLC transporters.  
THTR-1’s role in disease and adverse drug reactions 	
Thiamine Human Transporter 1 (THTR-1), which is encoded by SLC19A2, is a thiamine 
transporter expressed ubiquitously in many different tissues. However, THTR-1 is the main 
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thiamine transporter in pancreatic islet tissue and hematopoietic stem cells. Rare, deleterious 
variants in SLC19A2 cause thiamine-responsive megaloblastic anemia (TRMA), a syndrome 
characterized by deafness, diabetes and megaloblastic anemia (MA).31 MA is generally caused 
by folic acid or vitamin B12 deficiencies or drug-induced. Prescription drugs can induce MA 
through a variety of mechanisms.32 But, to date, the impact of these prescription drugs on THTR-
1 transporter activity and thiamine levels was unknown.  
Summary of Dissertation Chapters 	
The research described in this dissertation focuses mainly on GLUT2 and to a lesser extent, 
THTR-1. The overall goal of this dissertation is to understand the influence of rare variants in 
nutrient transporter genes (i.e. SLC2A2, SLC19A2) on drug response, disease expression and 
phenotype. In Chapter 2, the goal of the research is to determine if rare, SLC2A2 variants 
modulate initial therapeutic response to metformin. In Chapter 3, the aim of the study is to 
functionally characterize the impact of FBS-causal SLC2A2 variants on GLUT2 transporter 
function, structure and expression and relate that information to FBS phenotype. Here, we 
identified an in-frame deletion variant (p.Leu153_Ile154del) with residual transport activity that 
associated with a mild form of FBS. In Chapter 4, the aim of the study is to identify prescription 
drugs that can phenocopy or mimic the effects of rare, deleterious SLC19A2 variants (i.e. 
thiamine-responsive megaloblastic anemia). Two drugs known to induce megaloblastic anemia 
(omeprazole, erythromycin) were found to inhibit THTR-1 thiamine transport in vitro and 
associate with lower levels of thiamine pyrophosphate in a general patient population. In Chapter 
5, I summarize the results of the studies in this dissertation, highlight our major findings and 
discuss future studies needed to identify treatments that correct dysfunctional expression or 
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activity of SLC transporters and uncover the biological and physiological mechanisms that 
determine GLUT2’s relationship with metformin response. 
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Chapter 2: Design of a Massively Parallel Sequencing Study to Discover Rare 
Variants in SLC2A2 that Associate with Metformin Response. 
 
INTRODUCTION 	
Type 2 Diabetes (T2D) is a growing epidemic in the United States and globally. As of 2015, over 
30 million individuals in the U.S.1 and 1 in 11 adults worldwide have diabetes, most of whom 
have T2D.2 Heritability studies have estimated that 33% of the variance observed in this disease 
can be attributed to genetic factors3,4.   Thus, the genetic architecture of T2D has been under 
investigation for over two decades using powerful methods like genome-wide association studies 
(GWAS).5 A meta-analysis of thirty-two GWAS studies focused on T2D has demonstrated that 
various genes and single variants (i.e. at least 243 genome-wide significant loci) influence risk of 
developing T2D.6 The majority of these genome-wide significant loci each have small effect 
sizes (i.e. less than 10% change in risk) and do not drastically increase or decrease risk of 
developing T2D individually. Interestingly, common variants (minor allele frequency ≥5%) that 
associated with T2D development had risk ratios between 1.03-1.37 whereas low frequency and 
rare variants (minor allele frequency (MAF) < 5%) had higher risk ratios between 1.08 to 8.05, 
demonstrating that rare variants often have larger influences (or effect sizes) on T2D risk than 
common variants.  Rare variants can reveal novel biological pathways involved with T2D 
development.6   
 
According to the American Diabetes Association, first line treatment for T2D is metformin, a 
biguanide molecule.7 In 2017, 79 million prescriptions of metformin were generated in the U.S.  
In fact, globally, the use of metformin is so common that it has been detected in lakes and rivers 
used to produce potable water in Germany.8 In 2011, the first GWAS of metformin response was 
conducted, which found a genome-wide significant signal near ATM (common variants near 
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ATM, 2011).9 In 2014, with others, our laboratory, conducted the largest GWAS of metformin 
response in over 20,000 T2D patients taking metformin.10 Rs8192675, an intronic SNP in 
GLUT2, was the only variant to reached genome-wide significance; it was associated with 
improved response to metformin using change in hemoglobin A1c (HbA1c) as the 
pharmacologic endpoint.11  
 
Specifically, rs8192675 (C allele) was associated with a 0.17% (P = 6.6 × 10−14) greater 
reduction in hemoglobin A1c (HbA1c) versus the reference allele (T allele); this reduction was 
even larger in obese patients (0.33% reduction in HbA1c in obese patients who harbored the C 
allele). With an average percent reduction in HbA1c for patients initiating metformin of 
approximately 1%, the polymorphism accounted for 33% of the variance in response in obese 
patients and 17% of the variance in non-obese patients12 For other anti-hyperglycemic drug 
classes, except for insulin and sulfonylureas, the average percent reduction in HbA1c is 
approximately 0.5%.13,14  Thus, the presence of rs8192675 in a patient on metformin can provide 
over a third of the HbA1c reduction that most other anti-hyperglycemic drugs classes provide 
and two-thirds if the patient is obese. Importantly, the effect of rs8192675 on HbA1c reduction 
was specific to metformin. In contrast to the effect observed in patients using metformin, 
rs8192675 exhibited no net pharmacogenetic impact (beta = 0.04%, P = 0.44) on sulfonylurea-
induced HbA1c reduction. 
 
Consistent with the genetic analysis, in vitro reporter studies revealed a reduced expression of 
luciferase using an upstream region that contained the rs8192675 C-allele compared with the 
wild-type upstream region, suggesting this variant may influence SLC2A2 expression in-vivo. 
	 19	
The evaluation of 1,226 liver samples for expression quantitative trait locus (eQTL) analysis, 
revealed rs8192675 as the top cis-eQTL for SLC2A2, with the C allele associated with decreased 
(P = 4.2 × 10−12) SLC2A2 expression.11 A second, independent GWAS conducted by the German 
Diabetes Study group revealed that rs8192675 associated with metformin response in newly 
diagnosed Type 2 Diabetics using change in fasting blood glucose levels.15 Overall, these two 
GWAS provide substantial evidence that genetic polymorphisms in SLC2A2 (i.e. rs8192675) 
contribute to differing responses to metformin treatment.  
 
Despite the fact that rare variants generally have a larger effect on a phenotype versus common 
variants,6 the overwhelming majority of GWAS studies (disease or drug response) have not 
incorporated rare variants, to date.  This may be due to limitations in budget as sequencing may 
be costly, genotype calling, analysis software16,17 or standard statistical tests (i.e. linear or 
logistic regression) that are not powered to analyze rare variants.18,19,20,21 Several 
pharmacogenomic sequence association studies, which capture rare variants in the genome via 
next generation sequence technologies have found statistically significant signals from rare 
variants in genes identified from previous candidate gene or genome-wide association 
studies.22,23,24,25,26  
 
For example, a GWAS of children with acute lymphoblastic leukemia (ALL) identified several 
SLCO1B1 common variants that significantly associated with methotrexate clearance at a 
genome-wide level (p-value < 1.7 x 10-9).27 Three years later, Ramsey et al and colleagues then 
re-sequenced SLCO1B1 exons with the aim of identifying rare SLCO1B1 variants that influence 
methotrexate disposition.  They found eleven non-synonymous rare SLCO1B1 variants and one 
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non-synonymous less common variant that associated with metformin clearance. They also 
found that, after adjusting for genetic and non-genetic covariates, variance in methotrexate 
clearance attributable to SLCO1B1 rare variants accounted for 1.9% of the 10.7% variance in 
methotrexate clearance due to SLCO1B1.22 This example underscores the issue of “missing 
heritability” in GWAS, which tend to underestimate the variance explained by genetic variants 
compared to family-based heritability estimates.28   Though controversial, it has been proposed 
that this “missing heritability” in GWAS could be, in part, explained by rare variants, which are 
not evaluated in GWAS studies.  
 
Based on this, we hypothesize that rare variants (individually or in combination) in SLC2A2 will 
associate with and influence response to metformin. Our first objective was to design a study that 
uses next generation sequencing of DNA from a cohort of extreme metformin responders and 
non-responders to capture and analyze rare variants that would not otherwise be captured by 
genotyping platforms. Our second objective was to statistically analyze the influence of these 
rare variants and functionally characterize the impact of these rare variants on GLUT2 function 
and/or expression.  Here I describe the study design, discuss various statistical analyses that 
could be applied and highlight the general limitations of pharmacogenomic sequencing 
association studies.  Actual data analyses are forthcoming and will be reported at a later date. 
CLINICAL STUDY DESIGN  	
For this study, we used the METRO cohort (METformin RespOnse, N ~ 1000). METRO patients 
were selected from a large consortium of subjects with Type 2 Diabetes who have been on 
metformin for at least 3 months (total of 20,000 subjects) that exhibited the best (reduction in 
HbA1c > 1%) or the worst (no change or increase in HbA1c level) response to metformin 
	 21	
treatment. The premise behind this type of clinical study design, known as extreme trait design 
(ETD), is the observation that rare variants are generally enriched in individuals exhibiting 
extreme versions of a trait (disease or drug response). (Figure 2.1).29 For example, studies of 
human disease using ETD have identified novel genes and/or rare variants that associate with the 
presence or severity of complex diseases such as diabetic retinopathy, atrial fibrillation and 
Alzheimer’s disease.30,31,32  Additionally, studies of adverse drug reactions have employed ETD 
to identify variants that increase risk of serious adverse reactions, identifying a genetic marker 
that can be used proactively to prevent adverse reactions.23  
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Figure 2.1 Rare variant enrichment in extreme phenotypes of a trait. 
The figure shows the distribution of individuals with an extreme phenotype of a trait (blue 
person), the rare variant of large effect that associates with the extreme phenotype (green star) 
and the individuals with out that extreme phenotype (black person). In a small sample of the 
general population, the rare variant of large effect is at a low frequency (A). But in the larger 
general population, the rare variant of large effect associates with the extreme phenotype (B).  
 
 
 
 
 
 
 
	 23	
Patient selection for the METRO cohort was determined as follows.  First, to generate a 
phenotype distribution, the absolute change in HbA1c was plotted for each of 20,000 patients in 
the Kaiser Permanente Northern California database with a diagnosis of T2D who are initially 
placed on metformin.  Next, the top and bottom 2.5% (N ~ 500 per group) was selected from the 
distribution; the top 2.5% being extreme responders to metformin and the bottom 2.5% being 
extreme non-responders to metformin (Figure 2.2). Then these individuals were contacted via 
letters and/or telephone and recruited to enroll into the METRO study with a target goal of 500 
extreme non-responders and 500 extreme responders. Primary component analysis (PCA) was 
used to verify the genetic ancestry of each subject and to confirm a homogenous genetic 
population (European).   
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Figure 2.2 Phenotype (metformin response) distribution curve. 
The figure represents the phenotype distribution curve for 20,000 T2D patients who initiated 
metformin for at least 3 months. The number of patients in each “bin” is plotted on the y-axis 
and the change in HbA1c is plotted on x-axis. Five hundred patients with the largest change in 
HbA1c (top 2.5%) were selected as extreme responders and five-hundred patients with the 
smallest change in HbA1c (bottom 2.5%) were selected as extreme non-responders.  
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After recruitment of subjects and extraction of DNA, the stored genomic DNA samples of the 
1000 METRO patients were sequenced using next generation sequencing technology (GenScript 
Inc). Specifically, we conducted targeted sequencing of SLC2A2 by sequencing the eleven exons 
of SLC2A2 plus the 5’ and 3’ untranslated regions (UTR) of each sample. Raw sequence reads 
(fastq files) were processed, indexed, aligned, duplicates removed and variants called using the 
Sentieon pipeline ®.33 We targeted an average depth of coverage per base of at least 50X. 
Variants were stringently filtered then compiled into the finalized vcf file. Rare non-synonymous 
variants (missense, nonsense, in-frame indels) that are identified in the vcf file will be verified 
using PCR amplification and sanger sequencing (MCLAB Inc). 1000 Genomes has identified 
5154 genetic variants in SLC2A2; less than half of those variants (2258) have a MAF ≥ 0.001.34 
Table 2.2 lists the sample size needed to detect variants with each respective MAF assuming a 
99.9% probability of detection. 34,35 Once sequencing of SLC2A2 was completed and the genetic 
data processed and compiled, we detected 326 variants. 
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Table 2.1 Detection of low frequency variants varies by sample size. 
 
The table shows the minimum number of samples/patients needed to detect (at a 99.9% 
probability) a mutation at various minor allele frequencies (MAF). As the MAF of variants 
decreases, the required number of samples needed to detect those variants increases. At a sample 
size of 1000, there is a 99.9% probability to detect variants with a MAF ≥ 0.0034. 
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EVALUATION OF PROPOSED ANALYSES METHODS 	
The METRO cohort is a deeply phenotyped cohort that has collected dozens of clinical and 
laboratory traits such as HbA1c (pre and post-metformin treatment), serum creatinine, age, 
weight, and metformin dose.  Because the ETD divides the METRO cohort into two groups (i.e. 
cases and controls), we can conduct different types of statistical analyses. Below I describe the 
potential analyses that can be conducted. 
• First, we can use simple statistical analyses for categorical variables (chi-squared or fisher 
exact test) to count the number of mutations in cases and controls and evaluate if the 
differences in those counts are statistically significant.  
• Second, we can use simple statistical analyses for numerical variables (student’s t-test) by 
determining the average number of variants per person in cases and controls and testing if the 
difference in averages is statistically significant.  Conveniently, the same analysis can be 
repeated using different definitions of “variants” (i.e. common and rare variants, rare variants 
only, non-synonymous variants only, rare and non-synonymous variants only). 
• Technically, we could also conduct a logistic regression analysis and calculate the odds ratio 
(OR) of each SLC2A2 mutation being in case versus control patients. Logistic regression is 
often used in case-control GWAS studies. For instance, if a mutation has a MAF = 0.025 (i.e. 
a less common variant), a sample size of 1,352 would provide 80% power to detect the less 
common mutation with an odds ratio of 3 at an alpha level = 10-6.18 However, if a mutation 
with an odds ratio = 3 has a MAF = 0.01 (i.e. a rare variant), a sample size of 3,236 would be 
required to have 80% power to detect the mutation at an alpha level = 10-6.18 At a MAF = 
0.001, 31,510 individuals are needed to detect an odds ratio of 3 at 80% power.18 Thus we 
	 28	
are too underpowered to successfully identify rare variant associations with logistic 
regression.18,36,37 
• Additionally, because change in HbA1c is a numeric variable (and many other clinical 
phenotypes are numeric values), we can also conduct more complex statistical analyses to 
determine if the presence of these rare variants influences the direction or magnitude of 
HbA1c reduction.  Linear regression is often used in GWAS studies evaluating a numerical 
phenotype (i.e. blood pressure, height). But similar to the inherent issue of using logistic 
regression, linear regression is underpowered to detect rare variant associations. Essentially, 
a common variant with MAF = 0.1 would need 967 patients to detect change of 0.17% in 
HbA1c at a power = 0.8 and alpha = 0.05, but a rare variant with MAF = 0.01 would need 
8832 patients to detect change of 0.17% in HbA1c at a power = 0.8 and alpha = 0.05.38  
 
With the explosion of massively parallel sequencing data, newer statistical tests were developed 
in the last decade to detect rare variant associations that could not be feasibly detected with 
single marker tests (tests that analyze individual variants separately, e.g. logistic and linear 
regression).18 Multi-marker statistical tests, also known as aggregation association tests, jointly 
test the effect of all variants as a whole and determine if cumulative effect of the aggregated rare 
variants associates with the phenotype.39 Each type of aggregation association test provides 
advantages and disadvantages based on what is known about the underlying biology of the 
phenotype being evaluated.39  
• Burden test:  The most basic of these aggregation association tests is the burden test, which 
assesses “whether there is an excess of rare variants in cases or controls.”39 The approach 
aggregates multiple rare variants in a gene or region into a single “super’ variant then 
	 29	
performs the association test on the single “super” variant. Burden tests achieve the greatest 
power when the combined rare variants all have the same directional effect on the phenotype 
(Figure 2.3). However, the burden test becomes a disadvantage if the grouped rare variants 
individually affect the phenotype in different directions; the sums of the negative and 
positive effects neutralize and result in no association being detected.  
• Sequence kernel association test (SKAT): SKAT is a variance component test that was 
developed in 2011 to address this problem. Unlike burden tests, the SKAT test statistic is 
robust to aggregation of rare variants with negative and positive affects on the trait because it 
is the weighted sums of the squared variance 21,39 Both negative and positive variances are 
squared thus converting all the effects to positive before being summed together (Figure 2.3).   
Additional tests have been created which combine the power of burden tests (rare variants 
with the same effect) with the robustness of SKAT to the presence of variants with opposing 
effects. These tests (CMC, SKAT-O) can be especially effective in the presence of many 
non-causal variants.21 Because we cannot predict the direction of each rare variant’s effect on 
metformin response, the most fitting test to select for statistical analysis is SKAT (or SKAT-
O). 
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Figure 2.3 Burden and SKAT test statistic equations. 
The figure shows the equation for the test statistic of the burden test and SKAT test. In the 
burden test, Wj*Sj is summed for all rare variants then squared; thus positive Wj*Sj and negative 
Wj*Sj can neutralize each other when summed together. In the SKAT test, Wj and Sj are each 
squared before being summed creating a positive magnitude of effect for each variant before 
being combined.   
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LIMITATIONS OF STUDY DESIGN AND PROPOSED ANALYSES 	
Note that sequencing association studies that analyze rare variants have limitations that should be 
addressed before study initiation. The first involves the cost of NGS sequencing large numbers 
of DNA samples. The cost of NGS will vary depending upon the type of sequencing platform 
selected (Illumina vs Pacific Biosciences; whole genome versus whole exome versus targeted 
region sequencing) and number of samples to be sequenced.  Generally, the cost of whole 
genome sequencing per sample is more expensive compared to whole exome sequencing per 
sample or targeted region sequencing per sample.40 Budget restraints may require selection of a 
cheaper NGS platform to maximize the number of samples sequenced or selection of a smaller 
cohort in order to use an optimal, but expensive NGS platform. ETD may enrich for rare variants 
and improve detection power while keeping the total number of samples at an affordable level.  
 
The second limitation involves identifying replication cohorts to validate significant rare variant 
associations from the pharmacogenomic study. Since there are no more than ten published 
pharmacogenomic sequence association studies, a replication cohort is unlikely to exist. If a 
replication cohort does exist, a meta-analysis (seqMeta, R package) can be conducted to combine 
the two cohorts and provide increased power.21 If a replication cohort does not exist, the effect of 
the rare variant(s) on the phenotype can be validated in-vivo using transgenic animal models or 
clinical trials of humans that express the rare variant(s). 
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CONCLUSIONS AND NEXT STEPS  	
To summarize, we have designed metformin sequencing association study to discover and 
characterize rare SLC2A2 variants that contribute to metformin response. DNA samples from the 
METRO cohort, T2D patients who experienced a great (extreme responders) or poor (extreme 
non-responders) response to metformin, were sequenced and the genetic data processed and 
compiled into a vcf file. We explored several statistical tests, which can be used to analyze our 
data. The simplest methods involve counting the total number of variants in cases versus controls 
using a 2x2 contingency table (chi-square) or obtaining the average number of variants per 
person in cases versus controls (student’s t-test) then testing if the differences are statistically 
different.  
 
Complex aggregation tests (burden test, SKAT), which increase power to detect rare variant 
associations, have been used successfully for numerical phenotypes in normally distributed data. 
But because we employed ETD, our data are not normally distributed (top and bottom 2.5% of 
the distribution); thus these aggregation tests may not be ideal. Therefore, we will execute the 
simplest statistical analyses (chi-square, student’s t-test) and consider more complex analyses if 
needed. The next steps of this project involve the execution of the aforementioned data analyses 
and functional evaluation of relevant variants. The results will be reported at a later date.  									
	 33	
REFERENCES 
 
1.  Centers for Disease Control and P. Diabetes 2017 Report Card. Atlanta, Georgia; 2017. 
2.  Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus 
and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. 
doi:10.1038/nrendo.2017.151 
3.  Zhou K, Donnelly L, Yang J, et al. Heritability of variation in glycaemic response to 
metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol. 
2014;2(6):481-487. doi:10.1016/S2213-8587(14)70050-6 
4.  Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the 
Framingham Offspring Study. Diabetes. 2000;49(12):2201-2207. 
doi:10.2337/diabetes.49.12.2201 
5.  Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from 
GWAS? Ann N Y Acad Sci. 2010;1212:59-77. doi:10.1111/j.1749-6632.2010.05838.x 
6.  Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-
variant resolution using high-density imputation and islet-specific epigenome maps. Nat 
Genet. 2018;50(11):1505-1513. doi:10.1038/s41588-018-0241-6 
7.  15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. Diabetes 
Care. 2020;43(Suppl 1):S193-S202. doi:10.2337/dc20-S015 
8.  Trautwein C, Berset J-D, Wolschke H, Kummerer K. Occurrence of the antidiabetic drug 
Metformin and its ultimate transformation product Guanylurea in several compartments of 
the aquatic cycle. Environ Int. 2014;70:203-212. doi:10.1016/j.envint.2014.05.008 
9.  The GoDARTS and UKPDS Diabetes Pharmacogenetics Study G, The Wellcome Trust 
Case Control Consortium 2. Common variants near ATM are associated with glycemic 
	 34	
response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117-120. 
doi:10.1038/ng.735 
10.  Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is 
associated with glycemic response to metformin. Nat Genet. 2016;48(9):1055-1059. 
doi:10.1038/ng.3632 
11.  Zhou K, Yee SW, MetGen coauthors, Giacomini K PE. Variation in the Glucose 
Transporter Gene GLUT2 (SLC2A2) Is Associated with Glycaeic Response to Metformin: 
A MetGen Study.; 2016. 
12.  Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin 
treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446-454. 
doi:10.2337/dc11-1465 
13.  Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide 
(exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 
2 diabetes. Diabetes Care. 2004;27(11):2628-2635. doi:10.2337/diacare.27.11.2628 
14.  Hirst JA, Farmer AJ, Dyar A, Lung TWC, Stevens RJ. Estimating the effect of 
sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 
2013;56(5):973-984. doi:10.1007/s00125-013-2856-6 
15.  Rathmann W, Strassburger K, Bongaerts B, et al. A variant of the glucose transporter gene 
SLC2A2 modifies the glycaemic response  to metformin therapy in recently diagnosed 
type 2 diabetes. Diabetologia. 2019;62(2):286-291. doi:10.1007/s00125-018-4759-z 
16.  Wright CF, West B, Tuke M, et al. Assessing the Pathogenicity, Penetrance, and 
Expressivity of Putative Disease-Causing Variants in a Population Setting. Am J Hum 
Genet. 2019;104(2):275-286. doi:10.1016/j.ajhg.2018.12.015 
	 35	
17.  Weedon MN, Jackson L, Harrison JW, et al. Very rare pathogenic genetic variants 
detected by SNP-chips are usually false positives: implications for direct-to-consumer 
genetic testing. bioRxiv. January 2019:696799. doi:10.1101/696799 
18.  Witte JS. Rare Genetic Variants and Treatment Response: Sample Size and Analysis 
Issues. Stat Med. 2012;31(25):3041-3050. doi:10.1002/sim.5428 
19.  Dutta D. Multi - SKAT : General framework to test for rare - variant association with 
multiple phenotypes. 2019;(July 2018):4-23. doi:10.1002/gepi.22156 
20.  Wheeler E, Leong A, Liu C-T, et al. Impact of common genetic determinants of 
Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: 
A transethnic genome-wide meta-analysis. PLoS Med. 2017;14(9):e1002383. 
doi:10.1371/journal.pmed.1002383 
21.  Lee S, Abecasis GR, Boehnke M, Lin X. Rare-Variant Association Analysis: Study 
Designs and Statistical Tests. Am J Hum Genet. 2014;95(1):5-23. 
doi:10.1016/j.ajhg.2014.06.009 
22.  Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in 
pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 
2012;22(1):1-8. doi:10.1101/gr.129668.111 
23.  Weeke P, Mosley JD, Hanna D, et al. Exome sequencing implicates an increased burden 
of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. 
J Am Coll Cardiol. 2014;63(14):1430-1437. doi:10.1016/j.jacc.2014.01.031 
24.  Chua EW, Cree S, Barclay ML, et al. Exome sequencing and array-based comparative 
genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. 
Pharmacogenomics J. 2015;15(5):414-421. doi:10.1038/tpj.2015.9 
	 36	
25.  Li M, Mulkey F, Jiang C, et al. Identification of a Genomic Region between SLC29A1 
and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 
80405 (Alliance). Clin Cancer Res. 2018;24(19):4734-4744. doi:10.1158/1078-
0432.CCR-17-1523 
26.  Mak ACY, White MJ, Eckalbar WL, et al. Whole-Genome Sequencing of 
Pharmacogenetic Drug Response in Racially Diverse Children with Asthma. Am J Respir 
Crit Care Med. 2018;197(12):1552-1564. doi:10.1164/rccm.201712-2529OC 
27.  Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion 
transporter polypeptide associated with methotrexate pharmacokinetics and clinical 
effects. J Clin Oncol. 2009;27(35):5972-5978. doi:10.1200/JCO.2008.20.4156 
28.  van der Sluis S, Verhage M, Posthuma D, Dolan C V. Phenotypic complexity, 
measurement bias, and poor phenotypic resolution contribute to the missing heritability 
problem in genetic association studies. PLoS One. 2010;5(11):e13929. 
doi:10.1371/journal.pone.0013929 
29.  Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease 
through whole-genome sequencing. Nat Rev Genet. 2010;11(6):415-425. 
http://dx.doi.org/10.1038/nrg2779. 
30.  Shtir C, Aldahmesh MA, Al-Dahmash S, et al. Exome-based case-control association 
study using extreme phenotype design reveals novel candidates with protective effect in 
diabetic retinopathy. Hum Genet. 2016;135(2):193-200. doi:10.1007/s00439-015-1624-8 
31.  Tsai C-T, Hsieh C-S, Chang S-N, et al. Next-generation sequencing of nine atrial 
fibrillation candidate genes identified novel de novo mutations in patients with extreme 
trait of atrial fibrillation. J Med Genet . 2015;52(1):28-36. doi:10.1136/jmedgenet-2014-
	 37	
102618 
32.  Nho K, Corneveaux JJ, Kim S, et al. Whole-exome sequencing and imaging genetics 
identify functional variants for rate of change in hippocampal volume in mild cognitive 
impairment. Mol Psychiatry. 2013;18(7):781-787. doi:10.1038/mp.2013.24 
33.  Freed D, Aldana R, Weber JA, Edwards JS. The Sentieon Genomics Tools - A fast and 
accurate solution to variant calling from next-generation sequence data. bioRxiv. January 
2017:115717. doi:10.1101/115717 
34.  Consortium T 1000 GP. A global reference for human genetic variation. Nature. 
2015;526(7571):68-74. doi:10.1038/nature15393 
35.  Lee, S., Wu, M. C., Cai, T., Li, Y., Boehnke, M., & Lin X. Power and Sample Size 
Calculations for Designing Rare Variant Sequencing Association Studies.; 2011. 
36.  Demidenko E. Sample size determination for logistic regression revisited. Stat Med. 
2007;26(18):3385-3397. doi:10.1002/sim.2771 
37.  Demidenko E. Sample size and optimal design for logistic regression with binary 
interaction. Stat Med. 2008;27(1):36-46. doi:10.1002/sim.2980 
38.  Dupont WD, Plummer WDJ. Power and sample size calculations for studies involving 
linear regression. Control Clin Trials. 1998;19(6):589-601. doi:10.1016/s0197-
2456(98)00037-3 
39.  Li B, Liu DJ, Leal SM. Identifying rare variants associated with complex traits via 
sequencing. Curr Protoc Hum Genet. 2013;Chapter 1:Unit 1.26. 
doi:10.1002/0471142905.hg0126s78 
40.  Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 
2010;11(1):31-46. doi:10.1038/nrg2626 
	 38	
 
Chapter 3: Functional and Structural Analysis of Rare SLC2A2 Variants 
Associated with Fanconi-Bickel Syndrome and Metabolic Traits 
 
 
ABSTRACT 	
Deleterious variants in SLC2A2 cause Fanconi-Bickel Syndrome (FBS), a glycogen storage 
disorder, whereas less common variants in SLC2A2 associate with numerous metabolic diseases. 
Phenotypic heterogeneity in FBS has been observed, but its causes remain unknown. Our goal 
was to functionally characterize rare SLC2A2 variants found in FBS and metabolic disease-
associated variants to understand the impact of these variants on GLUT2 activity and expression 
and establish genotype-phenotype correlations. Complementary RNA-injected Xenopus laevis 
oocytes were used to study mutant transporter activity and membrane expression. GLUT2 
homology models were constructed for mutation analysis using GLUT1, GLUT3, and XylE as 
templates. Seventeen FBS variants were characterized. Only c.457_462delCTTATA 
(p.Leu153_Ile154del) exhibited residual glucose uptake. Functional characterization revealed 
that only half of the variants were expressed on the plasma membrane. Most less common 
variants (except c.593 C>A (p.Thr198Lys) and c.1087 G>T (p.Ala363Ser)) exhibited similar 
GLUT2 transport activity as the wild type. Structural analysis of GLUT2 revealed that variants 
affect substrate-binding, steric hindrance, or overall transporter structure. The mutant transporter 
that is associated with a milder FBS phenotype, p.Leu153_Ile154del, retained transport activity. 
These results improve our overall understanding of the underlying causes of FBS and impact of 
GLUT2 function on various clinical phenotypes ranging from rare to common disease. 
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INTRODUCTION 
 
Pathogenic variants in SLC2A2, the gene that encodes for the glucose transporter, GLUT2, have 
been associated with Fanconi-Bickel Syndrome (FBS; OMIM# 227810), a rare glycogen storage 
disorder that has over 100 documented cases published.1,2 These deleterious, rare variants (minor 
allele frequency < 1%) effectively abolish GLUT2 transporter function, which leads to 
significant physiological sequelae. Currently, forty-six SLC2A2 variants have been identified and 
associated with FBS; these include missense, nonsense, in-frame indels (insertions/deletions), 
frame-shift indels and splice site variants. FBS is an autosomal recessive disease; in order for 
FBS to manifest in an individual, the person must be homozygous or compound heterozygous 
with two pathogenic SLC2A2 variants. Figure 3.1 displays the location of many of the GLUT2 
variants that are causal for FBS; these variants are scattered throughout GLUT2. 
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Figure 3.1 Fanconi-Bickel syndrome (FBS) variant location within GLUT2 transporter 
secondary structure.  
An illustration of the secondary structure of GLUT2 that displays the location of all published 
missense (orange), nonsense (grey), and in-frame indel (green) SLC2A2 variants associated with 
FBS. The majority of these FBS variants had not been evaluated in-vitro to test their impact on 
GLUT2 membrane expression or function. We selected seventeen variants (red border) to 
functionally characterize in our study. Roman numerals I-XII represent each transmembrane 
helix in the GLUT2. The green pentagon labeled “Fru” represents fructose. 
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Common signs and symptoms of the syndrome include hepatomegaly, stunted growth and rickets 
due to renal losses of calcium and phosphate, high post-prandial and low pre-prandial blood 
glucose levels. These typical manifestations are directly related to the expression pattern of 
GLUT2 in particular body tissues (liver, kidney, intestine, and to a lesser extent pancreatic beta 
cells) 3. As the primary glucose transporter in hepatocytes, GLUT2 regulates the normal flux of 
glucose into and out of the liver, and its loss leads to excessive glycogen storage (resulting in 
hepatomegaly). In the kidney, GLUT2 is located in the proximal tubule and is involved in the 
reabsorption of glucose from urine into the blood. The absence of GLUT2 in the kidney causes 
massive glucosuria plus significant loss of minerals required for bone growth and strength 
(calcium, phosphate) leading to bone deformities.4  However, as with many diseases, FBS 
presents with a spectrum of phenotypes.  Whereas some patients develop severe symptoms that 
are recalcitrant to treatment such as bone fractures5,6, hepatocellular carcinoma7, liver failure and 
premature death8,9 , others present with a “milder” clinical picture (relatively normal growth, no 
hepatomegaly, minor kidney dysfunction) that can be corrected with conservative measures10.  
 
Although GLUT2 variants associated with published cases of FBS have been identified, the 
majority have not been evaluated for their impact on GLUT2 function. To date, only five FBS 
variants have been functionally characterized (c.724A>C, p.Ser242Arg; c.1330T>C, 
p.Trp444Arg; c.1250C>T, p.Pro417Leu; c.59G>A, p.Gly20Asp; c.372A>C, p.Arg124Ser)11,12.  
Furthermore, the relationship between the functional effects of any of the mutant transporters and 
the phenotypic presentation of the disease has not been established. Since 2000, many new cases 
of FBS from around the world have been identified revealing a host of novel variants, but these 
new variants have not been functionally evaluated or characterized.7,10,13,14,15, 16,17,18,19,20 Cases of 
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heterozygote carriers of FBS variants, i.e. parents or siblings of FBS patients, that experience 
glycemic perturbations (i.e. glycosuria, impaired glucose tolerance) have been documented 21and 
have led to speculation that GLUT2 proteins could exhibit a dominant negative effect (i.e. 
haploinsufficiency) in individuals heterozygous for an FBS GLUT2 missense variant. 
  
In addition to individuals who are homozygous for rare, deleterious variants in GLUT2 that are 
causal for FBS, those who harbor at least one less common (minor allele frequency between 1 - 
5%) or common (minor allele frequency > 5%) SLC2A2 allele may be at risk for various 
metabolic traits. For example, genome-wide association studies (GWAS) have identified 
common and less common variants in SLC2A2 that associate with an increased risk of Type 2 
diabetes (T2D)22, as well as increases in fasting glucose23,24, glycated hemoglobin levels 
(HbA1c)25,26 and even differential response to metformin.27 Furthermore, several less common 
SLC2A2 variants that are only found in specific populations significantly associate with 
increased risk of T2D, elevated blood glucose, and cholesterol levels and other metabolic 
perturbations (Type 2 Diabetes Knowledge Portal: http://www.type2diabetesgenetics.org). 
Pharmacochaperones are drugs that improve the expression of misfolded mutant proteins. 
Several pharmacochaperones are FDA-approved to treat mutated enzyme diseases (i.e. 
migalastat for Fabry disease) 29 and most recently, ionchannelopathies (i.e. tezacaftor or 
lumacaftor for cystic fibrosis).30. However, there are no FDA-approved small molecule drugs for 
genetic diseases caused by a mutant or misfolded SLC transporter protein. Additionally, 
premature termination codon (PTC) modulating agents are a structurally diverse group of 
compounds that interferes with the recognition of nonsense codons promoting the complete 
translation of protein that would have otherwise been truncated then degraded via nonsense 
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mediated decay. Various PTC-modulating agents (i.e. erythromycin, gentamicin, ataluren) have 
been clinically-evaluated for different genetic diseases (familial adenomatous polyposis (FAP), 
duchenne muscular dystrophy (DMD), cystic fibrosis) generating mixed results in efficacy. To 
date, there are no published data demonstrating improved readthrough of PTCs in genes 
encoding for SLC transporters.  
 
In addition to glucose, GLUT2 transports and distributes other important monosaccharides 
throughout the body (i.e. fructose, glucosamine)31,32 and has a broader substrate range than other 
GLUT transporters.33 Studies have identified other hexoses and pentoses (i.e. 1,5 
anhydroglucitol, ribose) as substrates of a carrier-mediated process in tissues that express 
GLUT2 (liver, kidney);34,35,36 using in-vitro studies, ribose was found to be substrate of mouse 
GLUT2.37 But, to date, these monosaccharides have not been directly tested to determine if they 
are substrates of human GLUT2.   
 
In this study, I performed detailed functional analyses of all reported, but uncharacterized 
missense and in-frame indel FBS variants, as well as less common variants that associate with 
metabolic perturbations. In order to determine the impact of these variants on GLUT2 transporter 
function, our studies focused on assessing the function of mutant or polymorphic transporters, as 
well as plasma membrane expression. A GLUT2 homology model was used to propose the 
molecular mechanisms by which particular FBS variants cause GLUT2 structural instability and 
abrogate GLUT2 transporter function. Subsequently, I tested the effectiveness of several 
pharmacochaperones and premature termination codon (PTC) modulating agents in specific 
FBS-associated variants (missense, indel and nonsense). Finally, we tested a variety of 
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monosaccharides (e.g. pentoses, hexoses) to determine if any are substrates of human GLUT2. 
Overall, this study creates a comprehensive catalog of the functional characteristics of all 
reported missense and in-frame indel variants associated with FBS and metabolic perturbations, 
along with a GLUT2 structure-function map. In vitro function for some of the GLUT2 variants is 
related to clinical phenotypic characteristics suggesting that understanding the functional effects 
of variants in GLUT2 may help explain the phenotypic heterogeneity within the FBS patient 
population, as well as the influence of SLC2A2 polymorphisms on metabolic traits.  
 
METHODS 
 
Chemicals and Reagents 	
The following radionuclides were obtained from American Radiolabeled Corporation, Inc (ARC) 
and Roche then tested as substrates of human GLUT2: [3H]-ribose (ARC), [3H]-xylose (ARC), 
[3H]-1,5 anhydroglucitol (Roche). The following pharmacochaperones compounds were obtained 
from Sigma Aldrich:  Alvespimycin (17-DMAG), 4-phenylbutyric acid (4-PBA), Corr-4a, 
vorinostat, luminespib, ursodeoxycholic acid (URDA). The following sterile-filtered PTC agents 
were obtained from Sigma Aldrich: G418, Ataluren.  
Mutation selection for functional and structural analysis 	
The approach for variant selection was divided into two categories: variants associated with FBS 
and variants associated with common metabolic traits. Published FBS case reports, case series 
and reviews were acquired via PubMed and various databases. Information on each FBS patient 
such as demographics, clinical signs and symptoms and genotype, if available, was collected. 
Cases that did not have clinical data or did not validate clinical FBS diagnosis with a genotype 
were excluded (approximately twenty cases). The compiled list of variants and associated 
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phenotypes (87 cases) is available online in the published supplemental (Supplemental Table 3.1, 
PMID: 30950137). We used the Type 2 Diabetes knowledge portal to only select missense 
variants associated with metabolic traits (e.g. T2D, HbA1c, fasting glucose, fasting insulin and 
body mass index; p-value < 0.05). Then we used 1000 Genomes Browser and gnomAD browser 
to determine the allele frequency of the variants in each population (1000 Genomes Consortium, 
2015). Based on this criteria, we selected five SLC2A2 variants that are rare in the general 
population, but found in less common frequencies in specific populations and ethnicities.  
Mutant plasmid generation using site-directed mutagenesis 	
For X. laevis oocyte studies, site-directed mutagenesis service, performed by GenScript®, was 
used to create 4 FBS in-frame deletions, 13 FBS missense, and 5 less common missense variants 
in the human GLUT2 expression vector (pSP64T-GLUT2) provided by Dr. Graeme I. Bell 
(University of Chicago). All capped cRNA (wild-type and mutant GLUT2) were synthesized in 
vitro from each respective pSP64T-GLUT2 plasmid using the mMessage mMachine SP6 kit 
(Thermo Fisher Scientific).  
For studies in mammalian cells, GLUT2 cDNA (RefSeq NM_000340.1, NP_000331.1) was 
cloned into the pcDNA5™/FRT mammalian expression vector (Thermo Fisher Scientific) to 
produce the pcDNA5-GLUT2 plasmid.  Site-directed mutagenesis service, performed by 
GenScript®, was used to introduce the previously mentioned variants plus four nonsense 
mutations (p.Arg301Ter, p.Arg365Ter, p.Trp395Ter, p.Trp420Ter) into the expression vector 
(pcDNA5). 
Radiolabeled substrate uptake assays in X. laevis oocytes  	
Ecocyte Bio Science LLC (Austin, TX) provided stage VI, defollicuted oocytes along with 
oocyte injection services. Six to ten oocytes were selected per construct and each oocyte was 
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injected with 50nL of saline, wild-type or mutant GLUT2 cRNA (40ng per oocyte). Oocytes 
were incubated on a shaker at 18°C in Modified Barth’s solution with gentamicin (NaCl 88mM, 
KCl 1mM, MgSO4 1mM, HEPES 5mM, NaHCO3 2.5mM, CaCl2 0.7mM, Gentamicin 
100µg/mL; Sigma-Aldrich) that was replenished every 24 hours. Forty-eight to seventy-two 
hours post-injection, thirty-minute uptake assays were performed using labeled [3H]-2-deoxy-
glucose (10µM total of 2-deoxy-glucose, PerkinElmer). Modified Barth’s solution was used as 
the uptake buffer.  Previous time range experiments revealed that 30 minutes was within the 
linear range of GLUT2 uptake. After uptake, oocytes were washed 5 times in cold uptake buffer 
then lysed in 0.5mL of 1% SDS (sodium dodecyl sulfate) solution (VWR International) for at 
least 1 hour. Radioactivity (disintegrations per minute) was measured using liquid scintillation 
counter machine. Radiolabeled substrate uptake rates were calculated by converting the DPM 
(disintegrations per minute) values of each oocyte to picomoles of substrate.  Using the same 
process as mentioned, several radioactive monosaccharides were evaluated to identify novel 
substrates of human GLUT2, including  [3H]-xylose, [3H]-1,5 anhydroglucitol (1,5 AG), [3H]-
ribose. Additionally, using the same aforementioned process, GLUT2 mutant oocytes were 
exposed to pharmacochaperones for 24 hours and their uptake of [3H]-2-deoxy-glucose (10µm) 
was measured. Figures are representative of 3-5 experiments, except Figures 3.6-3.9.   
Transfection and establishment of mammalian cell line transiently expressing 
GLUT2 reference and mutant cDNA 	
Flp-In™ 293 cells (human embryonic kidney cells, Thermo Fisher Scientific) were transfected 
with select pcDNA5/FRT-GLUT2 mutant constructs using Lipofectamine® LTX with Plus™ 
reagent according to the manufacturer’s instructions (Life Technologies) to confirm uptake and 
membrane expression results found in oocyte assays.  Approximately 200,000 Flp-In™ 293 cells 
were plated in 24-well format; once each well reached 90% confluence, transient transfection 
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was performed (4 replicates per construct).  Transfected cells were maintained in DMEM 
containing 10% (v/v) FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, and 100 µg/mL 
Zeocin (Thermo Fisher Scientific) at 37 °C and 5% CO2 for 48 hours. Thereafter, thirty-minute 
uptake assays were performed using [3H]-fructose (100 µM total of fructose).  Cells were lysed 
for one hour using 800 µL of lysis buffer (0.1N NaOH, 0.1% SDS) and the radioactivity of 
500µL of lysate was measured using a liquid scintillation counter machine. The DPM values 
were converted to picomoles of substrate. Total protein concentrations were determined using 
the bicinchoninic acid (BCA) assay using 25 µL of lysate per well (Thermo Fisher Scientific).  
Substrate uptake (in picomoles) was normalized by protein amount in each respective well. 
Using the same aforementioned process, cells were transfected with pcDNA5/FRT-GLUT2 
nonsense variant plasmids, exposed to PTC agents (G418, ataluren) for 24-48 hours, then their 
uptake of [3H]-ribose (1µM) was measured.  
Plasma membrane expression assays 	
Forty-eight to seventy-two hours post oocyte injection, GLUT2 plasma membrane expression 
experiments were conducted for each FBS and population-specific mutant (6-10 oocytes). 
Oocytes were placed in blocking buffer (1% bovine serum albumin solution) for 30 minutes at 
4°C. Next, oocytes were incubated in primary antibody solution (anti-GLUT2 mouse IgG 
antibody; MAB 1414, R&D systems) for 30 minutes at 4°C and then washed in blocking buffer 
six times. After washing, oocytes were transferred into secondary antibody solution (anti-mouse 
IgG VisUCyte HRP conjugate, R&D systems) for 30 minutes at 4°C then washed 6 times in 
blocking buffer and 6 times in ND96 buffer (NaCl 96mM, KCl 2mM, CaCl2 1.5mM, MgCl2 
1mM, HEPES 5mM; Sigma-Aldrich). Each oocyte was transferred to the well of a white 96-well 
plate (catalog #3912, Corning Inc); 100 µL of SuperSignal ELISA Femto (Fisher Scientific) mix 
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was added to each oocyte. One minute later, luminescence was measured using Glomax 96-well 
plate luminometer (Promega). All blocking and antibody solutions were produced using ND96 
buffer. Plasma membrane expression was defined as a mutant transporter whose average 
luminescence’s measurement was statistically similar to the average luminescence measurement 
of wild-type GLUT2. Using the same aforementioned process, GLUT2 mutant oocytes were 
exposed to pharmacochaperones for 24 hours and mutant transporter expression on the plasma 
membrane was measured via luminescence. Figures are representative of 3-5 experiments, 
except Figures 3.6-3.9. 
Kinetic studies of 2-deoxyglucose transport by GLUT2 and mutants 	
The transporter kinetics (Vmax  and Km) of functional mutants were generated and compared with 
wild-type GLUT2. Uptake was linear between 0 – 40 minutes (0-60 minutes tested) so 30 
minutes was selected to conduct uptake and kinetic studies.  The thirty-minute uptake of [3H]-
2DG in a range of 2DG concentrations (0-100mM) was measured as previously described and 
plotted as rate of uptake versus concentration to generate non-linear regression curves.  The Km 
and Vmax were calculated by fitting the curves to a Michaelis–Menten equation using GraphPad 
Prism 7 (La Jolla, CA). 
Statistical analysis 	
For comparison in radiolabeled uptake assays and plasma membrane expression assays, 
Student’s t-test and one-way ANOVA statistical tests were performed. Statistical analyses, as 
specified in the legends of the figures and tables, were performed to determine significance, and 
a p-value < 0.05 was considered significant. Unless specified, data in figures and tables were 
expressed as mean ± standard error of the mean (SEM). All experiments (except for experiments 
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represented by Figures 3.6-3.9) were performed at least 3 to 5 times and in 6 to 10 oocytes or in 
4 replicates in mammalian cell lines.  
Homology model construction for structural analysis 	
Homology models of GLUT2 were constructed with MODELLER v9.14 for mapping SLC2A2 
variants 39. Specifically, three conformational states of GLUT2 were modeled: an inward-open 
state based on the human GLUT1 (PDB identifier 4PYP; sequence identity of 51.7%) 40; an 
occluded state based on a Escherichia coli XylE transporter structure (4GC0; 23.8%) 41; and an 
outward-open state based on the human GLUT3 (4ZWC; 48.1%) 42. The alignment between 
GLUT2 and the template was generated using Promals3D 43. The models were evaluated and 
ranked with Z-DOPE 44 obtaining scores of -0.70, -1.20, and -0.85, suggesting they are 
sufficiently accurate for further analysis.  
To deduce the structural effects of the FBS missense variants on SLC2A2, variants that were 
functionally evaluated and expressed on the plasma membrane (nine mutations) were modeled 
and studied using molecular dynamics (MD) simulations.  
CHARMM-GUI Membrane Builder 45 was used to construct and introduce the variants to the 
GLUT2 homology model in the outward-open conformation in lipid bilayer for MD simulations 
46. Protein and the lipid bilayer system were parameterized with AMBER formatted 
CHARMM36m force fields (Brooks et al., 2009; Huang et al., 2017).47,48 Cholesterol (10%), 
phosphatidylcholine DOPC (55%), and phosphatidylethanolamine DOPE (35%) were used to 
construct the system in rectangular box with same x and y dimensions and at least 18 Å from 
protein to box edge. The final average area of the lipid bilayer was 7,600 Å2 with 13,704 TIP3P 
water molecules49 49and 0.15M NaCl concentration, with ~ 72,500-72,600 atoms for the various 
mutations. AMBER16 GPU-enabled PMEMD was used to perform the MD simulations.50,51 The 
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systems were minimized with 500 steps and equilibrated with NVT and NPT at 310.15 K, while 
hydrogens were constrained with SHAKE to enable 2-fs time step 52 1 ns of equilibration 
followed by 25 ns production run were performed for all systems. Trajectories were analyzed 
with CPPTRAJ 53 and visualized with PyMOL (The PyMOL Molecular Graphics System, 
Version 1.7 Schrödinger, LLC). 
 
RESULTS  	
Mutations in GLUT2, which are cause for FBS, are present throughout the protein, 
and in general, alter an evolutionarily conserved amino acid residue 	
I collected information on over 70 patients with FBS including the patient’s genotype, 
demographic characteristics, and available clinical information (Supplemental Table 3.1).  The 
demographic information reveals that FBS has been reported in every major human ethnic group. 
The first case of FBS was reported in Switzerland in 1949 54; the first Chinese patients diagnosed 
with FBS was in 2011 20; and the first African-American patient diagnosed with FBS was in 
2016.55 Our updated FBS case list includes more than ten novel amino acid variants that were 
published after the last published FBS review in 2002.2 These novel variants plus other FBS 
variants are scattered throughout the transporter, from the first transmembrane (TM) helix (e.g. 
c.59_60delinsAA, p.Gly20Glu) to the start of the carboxyl terminal tail (e.g. c.1439C>G; 
p.Thr480Arg) (Figure 3.1). PhyloP scores measure evolutionary conservation at individual 
alignment sites expected under neutral drift 56; positive scores indicate sites that are predicted to 
be conserved while negative scores indicate sites that are predicted to be fast-evolving. With few 
exceptions, most of the FBS SLC2A2 variants occur in areas that are highly conserved amongst 
one hundred vertebrate species (PhyloP scores ≥ 2) and highly conserved amongst GLUT1 to 
GLUT5 transporters (data not shown).56,57 
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The SNP annotation scores of the five SLC2A2 missense variants associated with 
metabolic traits 	
Five previously uncharacterized missense variants in SLC2A2 that have significant associations 
with metabolic traits were found to have allele frequencies between 0.1-5% in certain ethnic 
populations. Amongst these variants, Polyphen-2 58 predicted that one was probably damaging 
(c.301G>A, p.Val101Ile), two were possibly damaging (c.593C>A, p.Thr198Lys and 
c.1087G>T, p.Ala363Ser), and two were benign (c.1402C>G, p.Leu468Val, c.1556G>A, 
p.Gly519Glu). Among the three variants predicted to be probably or possibly damaging, two of 
them, p.Val101Ile and p.Ala363Ser, are conserved (PhyloP score > 2 and GERP score > 4). 
Interestingly, p.Val101Ile is predicted by various prediction scores to be damaging or deleterious 
(Polyphen-2, SIFT 59, CADD 60, GERP 61) and predicted by REVEL 62 to be partially damaging 
(score 0.46 (range from 0 to 1.0)).  In addition, valine in position 101 is conserved across human 
GLUT1 to GLUT5 (data not shown).57  
Functional characterization of seventeen mutations associated with FBS reveals 
a mutant transporter with residual function 	
All of the FBS mutant transporters had significantly reduced uptake of substrate compared with 
wild-type GLUT2 (Figure 3.2, one-way ANOVA F = 467.7; p-value < 0.0001). The uptake rate 
of 2DG (2-deoxy-glucose) by most FBS mutant transporters was comparable to that of saline-
injected oocytes. With the exception of one mutant (c.457_462delCTTATA, 
p.Leu153_Ile154del), all FBS mutants exhibited effectively no transport function, with uptake 
rates on average being approximately 0.5 pmol/0.5hr/oocyte (Figure 3.2).  Remarkably, 
p.Leu153_Ile154del still exhibited residual uptake of 2DG (2.174 pmol/0.5hr/oocyte), which was 
significantly higher than the other FBS mutants (one-way ANOVA F = 5.591, *p-value = 
0.0006) but still much lower than wild-type GLUT2 (student’s t-test 37.16 ± 1.1 vs. 2.174 ± 0.23 
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pmol/0.5hr/oocyte; p-value < 0.0001). Nine of the seventeen evaluated FBS mutant transporters 
were expressed on the plasma membrane and had similar expression to wild-type GLUT2 (one-
way ANOVA F-value = 0.6534; p-value = 0.74). The other eight mutants had partial or 
negligible plasma membrane expression compared to wild-type GLUT2 (Figure 3.2b, one-way 
ANOVA F-value = 23.05; p-value < 0.0001). 
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Figure 3.2 FBS mutant transporter uptake of 2DG and plasma membrane expression. 
The first graph (a) shows average transport rate of cRNA-injected X. laevis oocytes incubated 
with uptake buffer containing [3H]-2DG and 10µM of unlabeled 2DG for 30 minutes. All FBS 
mutant transporters had significantly reduced uptake of substrate compared with wild-type 
GLUT2 (one-way ANOVA F = 467.7; p-value < 0.0001) except for p.Leu153_Ile154del, which 
had significantly higher 2DG uptake compared to the other FBS mutants (one-way ANOVA F = 
5.591, *p-value = 0.0006). The second graph (b) shows luminescence emitted by cRNA-injected 
oocytes incubated sequentially with anti-GLUT2 (MAB #1414, R&D systems) and HRP-
conjugated antibodies. Nine of the seventeen evaluated FBS mutant transporters were expressed 
on the plasma membrane at similar levels to wild-type GLUT2 (one-way ANOVA F-value = 
0.6534; p-value = 0.74). The other eight mutants had partial or negligible plasma membrane 
expression compared with wild-type (one-way ANOVA F-value = 23.05; p-value < 0.0001). 
“PHL” in the figure represents phloretin, a canonical inhibitor of GLUT transporters. Data 
shown represent the mean ± SEM for 3 – 5 independent experiments.  
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Functional characterization of five missense variants in SLC2A2, associated with 
metabolic traits reveals mutations with partial function 	
We characterized five missense variants that were associated with metabolic traits. Three out of 
the five transporters had transport rates (one-way ANOVA F-value = 0.115, p-value = 0.95) 
statistically comparable to wild-type GLUT2 (Figure 3.3). p.Thr198Lys exhibited a partially 
reduced transport rate; it retained approximately 50% (23 pmol/0.5hr/oocyte) of transport 
activity compared to the wild-type (39.2 pmol0.5hr/oocyte, student’s t-test, **p-value = 0.005). 
The rate of 2DG uptake by p.Ala363Ser was similar to that of saline-injected oocytes (0.42 
pmol/0.5hr/oocyte).  
Except for p.Ala363Ser, all of the above mutants were expressed on the oocyte plasma 
membrane (one-way ANOVA F-value = 0.3502, p-value = 0.88) in a manner comparable to 
wild-type GLUT2. The estimated Km values of all mutant transporters associated with metabolic 
traits were not statistically different from that of wild-type GLUT2 (Figure 3.4, Table 1; one way 
ANOVA, p-value = 0.44). Similarly, the estimated Vmax values of all mutant transporters were 
not statistically different from that of wild-type GLUT2 (one-way ANOVA, p-value = 0.48) with 
the exception of p.Thr198Lys, which had a Vmax value much lower than the wild-type GLUT2 
transporter  (11±1.7 vs 53±2.0 nmol/0.5hr/oocyte, student’s t-test ***p-value = 0.0044). 
Michaelis-Menten curves could not be generated for p.Ala363Ser (signal undetectable in 
oocytes). 
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Figure 3.3 Less common mutant transporter uptake of 2DG and plasma membrane 
expression.  
The first graph (a) shows average transport rate of cRNA-injected X. laevis oocytes incubated 
with uptake buffer containing [3H]-2DG and 10µM of unlabeled 2DG for 30 minutes. The uptake 
rate of three out of the five mutant transporters (p.Val101Ile, p. Leu468Vale, p.Gly519Glu) was 
comparable to that of wild-type GLUT2 (one way ANOVA F= 0.1149; p-value =0.9509). The 
uptake rate of p.Thr198Lys (12 pmol/0.5hr/oocyte) was 42% lower than that of wild-type 
GLUT2 (40 pmol/0.5hr/oocyte, student t-test **p-value ≤ 0.0056). The uptake rate of 
p.Ala363Ser was negligible and similar to saline-injected oocytes. Figure 3b shows 
luminescence emitted by cRNA-injected oocytes incubated with anti-GLUT2 then HRP-
conjugated antibodies. The second graph (b) reveals that all mutant transporters were expressed 
on the plasma membrane in similar levels to that of wild-type GLUT2 (one way ANOVA F 
value = 0.3502, p-value = 0.88) except for p.Ala363Ser, which was not expressed on the oocyte 
plasma membrane (students t-test 7.4% vs 100%, **p-value < 0.0001). Data shown represent the 
mean ± SEM for 3 – 5 independent experiments.  
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Figure 3.4 Kinetic characterization of less common variants using 2DG.  
Michaelis-Menten curves for each population-specific variant were generated using 2DG 
concentrations ranging from 0.001 to 100mM. Km and Vmax values of each mutant with the 
exception of p.Ala363Ser were calculated by fitting the data to a non-linear regression curve. 
The Km and Vmax values of each mutant (mean + SEM) are listed in Table 3.1.  
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Table 3.1 Estimated kinetic parameters (Km, Vmax) for 2DG transport by GLUT2 less 
common variants. 
 Km (mM) 
[mean (SE)] 
Vmax (nmol/0.5hr/oocyte)  [mean 
(SE)] 
GLUT2 WT 34 (3.3) 53 (2.0) 
c.301G>A 
(p.Val101Ile) 
35 (12) 56 (8.1) 
c.593C>A 
(p.Thr198Lys) 
26 (10) 11 (1.7)*** 
c.1087G>T 
(p.Ala363Ser) 
n.d n.d 
c.1402C>G 
(p.Leu468Val) 
56 (13) 62 (8.4) 
c.1556G>A 
(p.Gly519Glu) 
31 (13) 45 (7.8) 
The Km values for the four measured mutants are statistically similar to wild-type GLUT2 (one-
way ANOVA p-value = 0.44). The Vmax values of these mutants are also similar (one-way 
ANOVA p-value = 0.48) except for the significantly reduced Vmax of p.Thr198Leu when 
compared with wild-type GLUT2 (11.7 vs 52.7, students t-test    ***p-value = 0.0044). Km and 
Vmax shown represent the mean and standard error [mean (SE)] for 2 independent experiments.  
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Functional characterization of GLUT2 mutant transporters in mammalian cells 
reveal some differences with mutants expressed in oocytes  	
The maximum increase in 2DG uptake in Flp-In™ 293 cells expressing full-length wild-type 
GLUT2 and empty vector was approximately 50-80% (data not shown). To improve the signal-
to-noise ratio, the uptake of radiolabeled fructose was tested. The fold difference in fructose 
uptake between pcDNA5-EV cells and pcDNA5-GLUT2 cells was approximately 2x (data not 
shown). The improvement in signal-to-noise ratio with fructose is due to its increased selectivity 
for GLUT2 compared to human GLUT1, GLUT3, and GLUT4 transporters that are present in 
immortalized mammalian cell lines.63  
 
Therefore, [3H]-fructose (fructose 100µM total concentration) was used as the radiolabeled 
substrate for the following Flp-In™ 293 radiolabeled substrate uptake experiments. As expected, 
the cells transfected with pcDNA5-GLUT2 FBS mutants had fructose uptake values similar to 
cells transfected with empty vector (one-way ANOVA, F=1.218, p-value = 0.2989). In contrast, 
fructose uptake was similar in cells transfected with mutants associated with metabolic traits 
(p.Val101Ile, p.Ala363Ser, p.Leu468Val, p.Gly519Glu) and cells transfected with full-length 
wild-type GLUT2 (one-way ANOVA, F=1.693, p-value = 0.1558), except for p.Thr198Lys.  
Fructose uptake rate in cells expressing p.Thr198Lys was slightly lower than in cells expressing 
wild-type GLUT2, though higher than in cells transfected with empty vector (student’s t-test p-
value <0.0001).  The results in mammalian cells exhibited a similar trend with the results in the 
oocytes, except for p.Ala363Ser.   
Unexpectedly, we found that p.Ala363Ser transporter, which was not expressed on the plasma 
membrane of X. laevis oocytes (Figure 3.3), was expressed well in Flp-In™ 293 cells and 
transported fructose at a similar rate as wild-type GLUT2. Interestingly, inhibition of the 
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proteasome in oocytes led to increased expression of p.Ala363Ser transporter on the plasma 
membrane, and the variant transporter had a similar activity as wild-type GLUT2 (data not 
shown). Discrepancies between heterologously expressed transporter activity in oocytes versus 
HEK293 cells have been previously observed. For example, Karniski and colleagues found that 
two out of the six variants in the sulfate transporter (DTDST) that were previously considered 
“partial activity” transporters in oocytes 64 demonstrated no activity in Flp-In™ 293 cells 
(Karniski et al., 2004).65 
 
Temperature-sensitive mutants may also function differently in oocytes (generally studied 
between 25-30oC and mammalian cells which are usually studied at 37oC.64,66,67 We determined 
that p.Ala363Ser is probably not temperature-sensitive because p.Ala363Ser transport function 
was similar to wild-type GLUT2 at 37°C (Flp-In™ 293 cells) and 18°C (oocytes plus 
proteasome inhibitor, data not shown). Our result showed that proteasome inhibition in Flp-In™ 
293 cells does not change the transport function of p.Ala363Ser, which suggests that the 
proteasome machinery of Xenopus laevis oocytes differs from HEK293 cells. Normally, 
expression patterns of heterologously expressed proteins are similar in Xenopus laevis oocytes 
and mammalian cells 68, but clear examples of differences in the expression of heterologous 
proteins between cell lines have been reported.65,66,67,69,70, 71,72,73  Therefore, extrapolation of these 
data to mammalian cells should be done with caution.  
Some FBS SLC2A2 alleles are represented in publicly available databases 	
Among the 17 FBS mutations characterized in this study, six were reported in various 
sequencing databases (c.115_117delATA, p.Ile39del; c.380C>A, p.Ala127Asp; 
p.Leu153_Ile154del; c.952G>A, p.Gly318Arg; p.Pro417Leu and c.1250C>G, p.Pro417Arg) like 
	 60	
the gnomAD and Geno2MP browsers, (Geno2MP: 
http://geno2mp.gs.washington.edu/Geno2MP/#/).75 Neither database reported a homozygote 
carrier of the six variants. Most of these variants have one to three allele counts, except for, 
p.Ile39del and p.Leu153_Ile154del which were more common (i.e. 8 and 22 allele counts, 
respectively, in gnomAD; 3 alleles of p.Leu153_Ile154del reported in Geno2MP).  
Structural analysis proposes molecular mechanisms of GLUT2 transporter 
dysfunction 	
SLC2A2 variants associated with FBS or metabolic traits that were expressed on the plasma 
membrane were selected for structural analysis. The structure of GLUT2 is currently unknown, 
however, structures of other human SLC2 members as well as the closely related prokaryotic 
homolog XylE, have been determined in atomic resolution, providing excellent templates to 
model GLUT2.76 We therefore generated homology models of GLUT2 in three different 
conformations to analyze the variants (Figure 3.5a). While the majority of these FBS variants 
occurred in the TM helices away from the substrate-binding site (> 5Å), we speculate that these 
variants affected function through altered packing of the TM helices or protein dynamics. The 
predicted effects of seven variants on the molecular attributes of GLUT2 that are needed for 
transport are described below.  
• c.96T>G, p.Asn32Lys and c.976_977delinsAA, p.Ser326Lys both lie in the extracellular 
channel of the transporter in TM1 and TM7, respectively. Their charged, bulky guanidinium 
side chain can sterically hinder the passage of the substrate through the channel (Figure 
3.5b). 
• c.609T>A, p.Ser203Arg is positioned on TM5; the variant introduces large steric clashes and 
electrostatic repulsion that alter the packing of TM5 and TM1 and influence TM1 dynamics. 
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Furthermore, the basic, guanidinium side chain may reach into the substrate-binding site, 
directly affecting substrate binding. 
• p.Gly318Arg, which is located next to substrate-binding site (Figure 3.5c), significantly 
influences the helix bending of TM7 while its large steric bulk affects the helix packing. 
These structural effects may alter the equilibrium of the conformation ensemble of the 
transporter and favour the inward-open conformation, resulting in the substrate being 
excluded from the substrate-binding site.  
• c.1246G>A, p.Gly416Ser is a variant along the transporter’s channel and can interact with 
the substrate. It is a variant on TM10 and in the critical (GPGPXP) helix kink formation, 
which can affect the helix packing and TM10 bending. In addition, p.Gly416Ser can directly 
interact with the binding site residues Glu412, and Gln193 on TM5, thus directly affecting 
binding site shape and biophysical properties. 
• p.Pro417Leu, a commonly reported FBS variant, was functionally characterized previously 
and shown to be expressed on the plasma membrane.11 According to our analysis, 
p.Pro417Leu directly and indirectly impacts several substrate-binding residues (Figure 3.5d). 
Specifically, p.Pro417Leu loses the backbone amide hydrogen bond to the i+4 residue 77 and 
distorts the natural (GPGPXP) helix kink formation, which can lead to the indole sidechain 
of p.Trp420 to twist away and prevent interaction with the substrate. This variant introduces 
large steric bulk affecting the tight helix packing, resulting in the distortion of binding site 
residues (p.Glu412, p.Asn349, and p.Gln193).  
• Another variant at position 417, p.Pro417Arg, also affects the kink of helix. Both 
p.Pro417Leu and p.Pro417Arg have the steric bulk that can affect the helix packing in the 
region (Figure 3.5d). But p.Pro417Arg establishes an extensive hydrogen bond network with 
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the surrounding residues and helices that potentially limits the expulsion movement of the 
other helices. p.Pro417Leu does not have this hydrogen bond network, and its steric bulk will 
expel the other packing helices. 
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Figure 3.5 Structural analysis of GLUT2 variants associated with FBS.  
GLUT2 homology model in an outward-open conformation (a). TM1-6, intracellular helix, and 
TM7-12 are represented as cyan, yellow, and salmon cartoon, respectively; the sugar maltose, 
derived from the template structure, is depicted as green sticks. Residues of interest and their 
mutations are depicted as magenta and yellow sticks, respectively.  
Asn32 locates on TM2 and exposes to the extracellular channel (b). p.Asn32Lys  (N32K) 
extends the reach of the residue sidechain into the channel by ~ 3.0 Å, potentially hindering the 
entry of substrate. Gly318 on TM7 is flanked by several bulky residues on TM9 and TM12, in 
addition to forms part of the SGXXG helix kink on TM7 (c). p.Gly318Arg (G318R) mutation 
introduces a bulky sidechain that clashes with bulky sidechains of TM9 and TM12 that disrupts 
the helix-helix packing interface, while affecting the formation of the native kink on TM7. 
Pro417 forms part of the TM10 helix kink and packs against TM5 and TM8, where its backbone 
carbonyl participates in the hydrogen-bond network of the substrate-binding site through 
interaction with the conserved Gln314 and Trp420. p.Pro417Arg (P417R) mutation, and 
similarly p.Pro417Leu, alters the formation of th TM10 helix kink (d). Furthermore, the 
introduction of a bulky sidechain clashes with Thr190 and Gln193, which disrupts the packing of 
TM5, TM8, TM10  as well as the integrity of the hydrogen-bond network of the substrate-
binding site. Hydrogen bonds and steric clashes are depicted as yellow dotted lines and red 
crosses, respectively. 
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Commonly used pharmacochaperones and PTC-modulating agents did not 
improve membrane expression or transport activity of GLUT2 FBS variants 	
Several pharmacochaperone compounds were tested to determine if any improved the expression 
and/or activity of characterized FBS variants, specifically p.239delCys, p.Leu389Pro and 
p.Thr480Arg (Figure 3.6). None of the tested pharmacochaperones (4-PBA 2mM, Corr-4a 
10µM, vorinostat 6mM, luminespib 100µM, URDA 500µM, 17-DMAG 500µM) provided a 
statistically significant increase in average transport activity in GLUT2 mutant oocytes compared 
to saline-injected oocytes (Figure 3.6a, student’s t-test, p-value ≥ 0.1). Similarly, there was no 
statistical difference in average expression of mutant transporters on the plasma membrane (one-
way ANOVA, p-value ≥ 0.21) compared to baseline (Figure 3.6b).  
 
Additionally, two PTC-modulating agents (G418 100µM, Ataluren 50µM) were tested to 
evaluate their ability to increase the transport activity of four FBS nonsense variants 
(p.Arg301Ter, p.Arg365Ter, p.Trp395Ter, p.Trp420Ter; Figure 3.7). Exposure to G418 100µM 
or ataluren 50µM did not increase the average uptake of ribose in HEK cells transfected with any 
of the four GLUT2 nonsense plasmids (one-way ANOVA, p-value > 0.05; Figure 3.7).   
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Figure 3.6 GLUT2 mutant oocytes exposed to pharmacochaperones.  
Radiolabeled uptake ([3H]-2-deoxyglucose) (a) and plasma membrane expression (b) 
experiments were conducted with X.laevis oocytes injected with human GLUT2 wildtype or 
mutant cRNA (40ng) or saline. Oocytes were pre-exposed to MBS buffer containing specific 
concentration of each pharmacochaperone for 24 hours. Fourty-eight hours later experiments 
were conducted. Data shown represents the mean ± SEM for two independent experiments.  
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Figure 3.7 HEK cells transfected with GLUT2 nonsense plasmids exposed to PTC-
modulating agents. 
The graph shows the uptake of ribose in Flp-In™ 293 cells transfected with emptye vector, 
GLUT2 wildtype or four FBS nonsense variant plasmids with or without exposure to G418 
(100µM) or Ataluren (50µM). 
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Three novel substrates of human GLUT2 were identified 
 
A variety of radionuclide monosaccharides ([3H]-ribose, [3H]-xylose, [3H]-1,5 AG, [3H]-
galactose, [3H]-glucosamine) and disaccharides ([3H]-sucrose) were evaluated to identify 
additional substrates of human GLUT2. As shown in Figure 3.8, xylose, 1,5 AG and ribose 
exhibited approximately a 3-fold, 5-fold and 30-fold higher uptake in oocytes expressing GLUT2 
compared with saline-injected oocytes (students t-test, p-value < 0.005), respectively, suggesting 
that these compounds are substrates of the transporter.  
 
The kinetic parameters (Km, Vmax) of each novel substrate for GLUT2 were evaluated (Figure 
3.9). Notably, the Vmax of ribose and 1,5 anhydroglucitol for GLUT2 was similar to or greater 
than that of glucose, (46 vs 110 vs 51 nmol/oocyte/30min, respectively), whereas the Km of 
ribose and 1,5 anhydroglucitol was much larger than that of glucose (177 mM vs 148 mM vs 17 
mM, respectively) suggesting that GLUT2 is a low affinity, high capacity ribose and 1,5 
anhydroglucitol transporter. The kinetics of xylose were comparable to 2DG for GLUT2. 
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Figure 3.8 Discovery of novel substrates of GLUT2 transporter. 
Radiolabeled substrate ([3H]-2-deoxyglucose, [3H]-xylose, [3H]-1,5 anhydroglucitol (1,5 AG), 
[3H]-ribose) experiments were conducted with X.laevis oocytes injected with human GLUT2 
wild-type cRNA (40ng) or saline. Oocytes were exposed to buffer solution containing 
radiolabeled substrate with and without phloretin (PHL), a canonical GLUT transporter inhibitor. 
Duration of the uptake was 0.5 hour and rates were calculated into fentimoles of substrate. Data 
shown represents the mean ± SEM for two independent experiments.  
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Figure 3.9 Kinetic evaluation of GLUT2 novel substrates. 
Kinetic experiments were conducted with radiolabeled substrate ([3H]-2-deoxyglucose, [3H]-
xylose, [3H]-1,5 anhydroglucitol (1,5 AG), [3H]-ribose) in combination with a series of unlabeled 
substrate concentrations (ranged from 0 - 300mM) using X.laevis oocytes injected with GLUT2 
wild-type cRNA (40ng).  Data was fitted to a Michaelis-Menten curve and kinetic parameters 
were estimated (Km, Vmax). Data shown represents the mean ± SEM for two independent 
experiments. 
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DISCUSSION 
 
In this study, I performed a comprehensive functional characterization of seventeen SLC2A2 
missense and in-frame indel mutant transporters associated with a range of FBS phenotypes and 
five SLC2A2 missense variants associated with various metabolic perturbations (e.g. T2D, 
elevated HbA1c concentration, increased fasting glucose levels).  Previously, only five FBS 
mutant transporters had been characterized out of over 40 known variants and to our knowledge, 
only three SLC2A2 missense variants associated with metabolic traits have been characterized 
(c.329C>T, p.Thr110Ile; c.203C>T, p.Pro68Leu and c.589G>A, p.Val197Ile.7,11,13,16,17,55 
Generally, in order for FBS to manifest in an individual, the person must be homozygous or 
compound heterozygous for deleterious SLC2A2 variants.  That is, FBS is, in most cases, an 
autosomal recessive disease.  In this study, following characterization of variants associated with 
FBS, various pharmacochaperones and PTC-modulating agents were used in an attempt to 
recover some of the lost function of the mutant transporters.  
 
The functional and structural evaluation of these variants led to four major findings.  First, 
variants associated with FBS virtually abolished transport function; however, one variant, 
p.Leu153_Ile154del, found in two cases of mild FBS, exhibited residual transport function. 
Second, about half of the FBS mutant transporters were not expressed (or expressed at low 
levels) on the plasma membrane, whereas the other half were expressed on the membrane but 
exhibited no transport activity. Third, structural analysis provided a mechanistic rationale for the 
deleterious effects of GLUT2 genetic variants that were expressed on the plasma membrane. 
Fourth, two less common variants, p.Thr198Lys and p.Ala363Ser, which are associated with 
increased glycated hemoglobin levels and T2D, exhibited reduced activity in oocytes. Below we 
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discuss each of these findings in the context of the literature.  This discussion is followed by 
discussions of our attempts to recover function of GLUT2 mutants with small molecule 
modulators of protein processing and our discovery of new substrates of GLUT2. 
 
First, of the seventeen variants in GLUT2 that had not previously been characterized, all but one 
(p.Leu153_Ile154del) abolished transport function. To the best of our knowledge, 
p.Leu153_Ile154del is the first SLC2A2 variant associated with FBS that results in a GLUT2 that 
retains some function, albeit minimal. The patients documented with a mild form of FBS were 
compound heterozygotes for the variants, p.Leu153_Ile154del and p.Pro417Arg.  Our data show 
that p.Pro417Arg has no activity. Though speculative, the data suggest that the residual activity 
of p.Leu153_Ile154del transporter was sufficient to rescue the severe phenotype commonly 
associated with FBS, resulting in a milder phenotype. The data may suggest that the meager 
function of one GLUT2 allele can significantly mitigate the most severe signs and symptoms of 
FBS. This has been demonstrated in other rare genetic diseases in which variants that result in 
partially active enzymes, transporters or channels are associated with a mild to moderate form of 
the disease and variants that result in non-functional enzymes, transporters or channels lead to 
the most severe forms (e.g. DTDST variants and chrondrodysplasias).65,69  
 
Second, the loss of function of about half of the mutant GLUT2 transporters was due to lack of 
expression on the plasma membrane.  Various mechanisms for improper sorting of mutant 
transporters in GLUTs and other SLCs have been described. 78,79,80,70,81 Generally, these 
mechanisms involve the retention (in ER or Golgi apparatus) and eventual destruction of 
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aggregated or misfolded mutant protein or the misdirection of mutant protein to the incorrect 
membrane.79,80,70,81,82  
 
GLUT1, GLUT3 and GLUT4 have known sorting sequences, DSQV 78, DRSGKDGVMEMN 83, 
and FQQI, TELEY, LL 84, respectively, that localize these GLUTs to their extracellular or 
intracellular membrane compartments. GLUT1 variants that occur near phosphorylation motifs 
that enhance membrane localization have been shown to reduce or prevent membrane expression 
of transporters, leading to GLUT1 deficiency syndromes.85 MetaServer, a tool that predicts 
peptide binding sequences within proteins, predicted several sequences in GLUT2 that could bind 
to proteins that regulate membrane trafficking.86,87,88,89  Of the 18 sequence-motifs in GLUT2 
predicted to harbor binding sites for proteins that regulate trafficking, one is changed by an FBS 
variant characterized in our study (c.715_717delTGT, p.239delCys).  Consistently, p.239delCys 
was not expressed on the plasma membrane. However, because these predicted motifs have not 
been validated in vitro, further work is needed to characterize the regulatory proteins and 
mechanisms by which these mutants alter plasma membrane expression of GLUT2. 
 
Third, we observed that many variants associated with FBS (nine out of the seventeen FBS 
mutant transporters) result in expression levels on the plasma membrane that are comparable to 
levels of the wild-type GLUT2. Computational analysis of seven out of the nine expressed FBS 
variants revealed several potential mechanisms by which FBS variants may disrupt transporter 
activity: steric hindrance of substrate channel (e.g. p.Asn32Lys and p.Ser326Lys), distortion of 
substrate-binding residues (e.g. p.Ser203Arg, p.Gly416Ser), and instability of TM helices and 
the overall transporter structure (e.g. p.Gly20Glu). These findings expand on previous findings 
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of structural analysis of pathogenic SLC2A1 variants that result in GLUT1 deficiency, which 
suggest that the vast majority of pathological GLUT1 disrupt helix-helix interactions and lead to 
structural instability of the transporter.90  
 
For instance, variants located at or near the substrate channel pathway in GLUT1 have been 
found to destabilize TM helix-helix interactions and helix packing (e.g. 
NM_006516.2:c.197C>T, p.Ser66Phe; NM_006516.2:c.929C>T, p.Thr310Ile)90 whereas our 
analysis showed rare GLUT2 variants that reside on either side of the substrate entrance (e.g. 
p.Asn32Lys and p.Ser326Lys; Figure 3.1, Figure 3.5) block the translocation pathway via their 
bulky, polar side chains.  Similarly, p.Gly318Arg, which is located next to GLUT2 substrate-
binding residues, affected TM7 helix bending and packing via it large steric bulk resulting in 
conformational inflexibility. Only one pathogenic GLUT1 variant directly impacted sugar-
interacting residues (1 of 7)90, whereas three of the nine FBS variants evaluated affected 
substrate-binding residues in GLUT2. For GLUT1, a series of engineered variant in the Ile168 
residue, located next to the hinge residue Gly167, which is adjacent to the sugar-binding site, 
abolished GLUT1 function via increased rigidity and steric hindrance.91 Future studies are 
needed to confirm the mechanisms predicted by the structural model for each of the GLUT2 
variants. Overall, these findings suggest that the majority of pathogenic SLC2 variants disrupt 
proper packing and dynamics of the TM helices or affect the shape and biophysical properties of 
the substrate binding site, which in turn leads to ineffective transport.  
 
Our final finding, which was not unexpected, was that most of the less common variants that had 
not been associated with FBS showed similar function to the reference GLUT2 (Figure 3.3). 
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These variants, most of which retained normal GLUT2 transport activity, have been associated, 
but at weak p-values, with various metabolic traits (e.g. T2D, high body mass index). The minor 
allele of p.Val101Ile and p.Gly519Glu are on the same haplotype with the reference allele (T) of 
rs8192675, a known eQTL (expression quantitative trait locus) that associates with increased risk 
of T2D 92. The minor allele of p.Leu468Val, which is associated with increased risk of T2D 
(OR=1.75, p=0.017) and fasting glucose (beta=0.58, p=0.003) is on the same haplotype with the 
reference G-allele of p.Thr110Ile, which itself has been associated with increased risk of T2D 
and fasting glucose. Structural analysis revealed that p.Thr198Lys (MAF < 0.5%), which 
displayed reduced substrate uptake in oocytes and Flp-In™ 293 cells (Figure 3.4, Table 3.1), 
may restrict helix movement and cause disturbance to the protein-lipid interface because of the 
charged lysine. This, along with a large reduction in glucose transport capacity (Vmax), may 
explain the statistical associations of p.Thr198Lys with increased hemoglobin A1c levels 
(p=0.012).  
 
Despite exposing three FBS missense variants and four FBS nonsense variants to a structural-
varied pharmacochaperones and PTC-modulating agents, no increases in expression and/or 
activity were observed (Figure 3.6, Figure 3.7). There is in-vitro evidence of select 
pharmacochaperones (phenylbutyrate, ibogaine, noribogaine) increasing the expression and/or 
activity of missense mutant SLC transporters (OCTN2/SLC22A5, DAT/SLC6A3, 
SERT/SLC6A4).93,94 But this area/topic is significantly understudied compared with the large 
amount of in vitro and in vivo efficacy data of pharmacochaperones in misfolded enzyme 
diseases. A lack of high-resolution structures for the vast majority of SLC transporters95 
(including GLUT2) make it difficult to simulate accurate models of transporter dynamics, which 
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ultimately contribute to a poor mechanistic understanding of transporter function and a lack of 
potential therapeutic interventions.94  
 
Similarly, several PTC-modulating agents have demonstrated in vitro and in vivo efficacy in FAP 
and DMD, but in vitro increases in transporter expression by these agents have only been 
reported a few times (i.e. ABCC6, CTNS/SLC66A4).96,97 High-throughput virtual screens using 
high resolution structures (crystal or cryo-elecronmicroscopy structures) of wildtype GLUT2 and 
partial/residual function GLUT2 mutants (i.e. p.Leu153_Ile154del) are needed to fast track 
discovery of pharmacochaperones and allosteric activators of GLUT2. Furthermore, establishing 
high-throughput in vitro screens for GLUT2 nonsense variants could expedite identification of 
novel compounds that promote PTC readthrough of FBS nonsense mutations.  
 
Finally, in this study, we discovered three previously unreported substrates of human GLUT2: 
1,5 AG, ribose and xylose. Previously, the mechanism of 1,5 anhydroglucitol (found in nearly all 
foods) absorption in the intestine and secretion in the kidneys was unknown, 34,98,36 but assumed 
to be carrier-mediated. 1,5 AG has an inverse relationship with glucose in the blood; the higher 
the 1,5 AG level, the lower the glucose level. Glycomark, a 1,5 AG clinical lab test, is approved 
by the Japanese Pharmaceuticals and Medical Devices Agency to measure and monitor short 
term glycemic control in diabetics.98   
 
Ribose is sold as a dietary supplement to improve and accelerate muscle recovery after intense 
exercise.  Based on the manufacturers’ daily dose recommendations (15 grams/day)99,100, the 
estimated intestinal concentration of ribose is 133 mM, close to the Km for GLUT2.  
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Administration of ribose (intravenous or oral) has been associated with transient 
hypoglycemia.101 Additional studies are needed to determine how GLUT2 influences ribose 
distribution and synthesis via the pentose phosphate pathway.  
  
The clinical use of xylose is rare when compared to 1,5 AG or ribose.  For example, intestinal 
absorption of xylose is used (rarely) as a clinical diagnostic test to determine if a patient’s 
intestinal tract is absorbing nutrients and functioning properly.102  Consumption of xylose in 
combination with sucrose reduced serum glucose and insulin levels compared with those who 
consumed sucrose-only beverages.103 The Km and Vmax of GLUT2 for xylose, which is similar to 
that of glucose (Figure 3.9), suggests that competitive inhibition between xylose and glucose for 
GLUT2 may occur.   	
CONCLUSIONS 
 
This comprehensive characterization of variants associated with FBS reveals that about half of 
the mutant transporters are expressed on the plasma membrane but do not function, and the other 
half are not significantly expressed on the plasma membrane. Further, we report for the first time 
that the in-frame deletion variant, p.Leu153_Ile154del, has residual glucose uptake. In contrast, 
the majority of the five SLC2A2 missense variants associated with metabolic traits have normal 
glucose uptake and are expressed on the plasma membrane. The structural analysis corroborates 
the functional studies and provides mechanistic insights into how these low frequency variants 
inactivate or reduce GLUT2 transporter activity. The functional and structural information 
gained in this study suggests that different strategies should be used to produce targeted, safe and 
effective therapies for FBS and possibly other GLUT-related diseases.	
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Chapter 4: Pharmacologic inhibition of THTR-1 in hematological tissues as a 
potential mechanism of drug-induced megaloblastic anemia 
  
ABSTRACT 	
Megaloblastic anemia (MA) is characterized by the presence of enlarged, immature red blood 
cells in the bone marrow and develops as a result of ineffective DNA synthesis in rapidly 
dividing hematopoietic stem cells. Exposure to specific drugs may cause drug-induced MA. An 
infrequent cause of MA is thiamine responsive megaloblastic anemia (TRMA), a genetic 
disorder caused by deleterious mutations in SLC19A2 (encodes for thiamine transporter, THTR-
1).  THTR-1 inactivity leads to thiamine deficiency in hematopoietic stem cells resulting in MA.  
The major objective of our study was to determine whether drugs known to cause MA inhibit 
THTR-1 as a potential mechanism contributing to the anemia. In addition, we explored chemical 
properties of the THTR-1 inhibitors and used electronic health records (EHR) to validate our 
results. Drugs associated with MA were screened for THTR-1 inhibitor activity; IC50 curves were 
generated for drugs identified as inhibitors.  Electronic health record information from patients 
on clinically relevant THTR-1 inhibitors was extracted and analyzed using R software.  
 
Of the 63 drugs screened, ten inhibited THTR-1 transport ≥ 50% at 1 mM. IC50 curves, which 
were generated for seven drugs, indicated inhibition potencies ranging from 20 to 430 µM. Two 
of the seven drugs were predicted to have systemic plasma concentrations between 10 - 60% of 
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their IC50 values. LogP was statistically higher in the THTR-1 inhibitors compared to the non-
inhibitors (p-value < 0.03). Two of the inhibitors, omeprazole and erythromycin, were predicted 
to inhibit THTR-1 at clinically relevant systemic concentrations and EHR data showed that use 
these drugs was significantly associated with reduced thiamine pyrophosphate (TPP) levels (p-
value < 0.0016).  
In conclusion, our study suggests a novel mechanism for drug-induced MA; specifically, 
inhibition of THTR-1, which may phenocopy TRMA and potentially contribute to the 
development of MA. 
INTRODUCTION 
 
Megaloblastic anemia (MA) is a term that describes a heterogeneous set of anemias that 
are characterized by the presence of enlarged, immature red blood cells, called megaloblasts, in 
the bone marrow. MA develops as a result of ineffective DNA synthesis in rapidly dividing 
hematopoietic stem cells.1   
 
Major causes of MA include vitamin deficiencies (i.e. vitamin B12, folic acid; Figure 4.1A) and 
exposure to certain drugs,2 also known as drug-induced megaloblastic anemia (DIMA) (Figure 
4.1). DIMA can be caused by a variety of drugs that inhibit DNA synthesis at different points of 
the pathway.2  For example, drugs can cause MA by reducing cellular availability of vitamin B12 
or folic acid through “interference with the absorption, plasma transport, or delivery of folate or 
vitamin B12, competition for reducing enzymes, or end-product inhibition of cofactor-mediated 
reactions” (Figure 4.1A, #1, #2).2  Folic acid and Vitamin B12 are required for the synthesis of 
thymidine, one of four nucleoside bases used for DNA synthesis. Furthermore, drugs can act as 
purine and pyrimidine antagonists or analogues, also causing reduction in DNA synthesis. For 
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example, certain chemotherapies (e.g., 5-fluorouracil), immune antagonists (e.g. leflunomide), 
and antiviral agents (Figure 4.1B, #4) may act as nucleoside antagonists or analogs, thus 
reducing DNA synthesis.  Additional mechanisms of drug-induced MA include inhibition of key 
enzymes such as dihydrofolatereductase (Figure 4.1B, #3). Interestingly, some drugs cause MA 
through unknown mechanisms.2  
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Figure 4.1 Mechanisms of drug induced megaloblastic anemia. 
Megaloblastic anemia (MA) is a type of anemia that occurs as a result of inhibition of DNA 
synthesis during red blood cell production. Common causes of MA involve a disruption in folic 
acid or vitamin B12 absorption (#1, #2; Figure 4.1A). The etiology of drug induced MA can 
include drugs that reduce in folic acid absorption (#1), drugs that reduce vitamin B12 absorption 
(#2), drugs that inhibit dihydrofolatereductase (DHFR, #3) and drugs that inhibit 
purine/pyrimidine synthesis (#4) (Figure 4.1B). An occasional cause of MA includes thiamine 
transport deficiency (THTR-1; #5) (Figure 4.1B).  MA is characterized by abnormally large, 
immature red blood cells.  
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In addition to common causes of MA such as vitamin deficiencies or use of particular 
prescription drugs, an infrequent cause of MA is an autosomal, recessive disorder known as 
thiamine-responsive megaloblastic anemia (TRMA). This syndrome is characterized by three 
hallmark signs: MA, non-autoimmune type 1 diabetes and sensorineural hearing loss.3   TRMA 
is caused by deleterious mutations in the SLC19A2, which encodes for Thiamine Human 
Transporter 1 (THTR-1), which is expressed ubiquitously in many different tissues (e.g. skeletal 
muscle, cardiac muscle, liver, kidney, pancreas and heart.4 THTR-1 is the main thiamine 
transporter in pancreatic islet tissue and hematopoietic progenitor cells.5, 6 Interestingly, TRMA 
patients7 and knockout mice (Slc19a2 -/-)8 demonstrate normal intestinal thiamine uptake and 
normal plasma thiamine levels in contrast to humans and mice deficient in THTR-2 (encoded by 
SLC19A3), a second thiamine transporter expressed mainly in the intestine, liver and kidney.  
THTR-2 deficiency results in significantly reduced intestinal thiamine uptake and reduced 
plasma thiamine levels, but has not been associated with TRMA.9 
 
The mechanism for TRMA, similar to MA from other causes, is related to inefficient DNA 
synthesis.  In particular, the active metabolite of thiamine, thiamine pyrophosphate (TPP), serves 
as a crucial cofactor for transketolase, the primary enzyme used in the pentose phosphate 
pathway for de novo production of ribose 10. Ribose is a necessary precursor for nucleic acid 
synthesis.  Several studies have found that a lack of thiamine in fibroblasts from patients with 
TRMA or in fibroblasts from Slc19a2 -/- mice exhibit significant reductions in ribose levels and 
deoxyribose levels and accordingly, reduced nucleic acid synthesis.10,11,12  
Based on the finding that TRMA and DIMA have similar mechanisms and that certain 
drugs associated with DIMA inhibit THTR-1 (i.e. trimethoprim),2,13 we hypothesized that 
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a potential novel mechanism for DIMA may be through inhibition of THTR-1, 
phenocopying TRMA.  To test our hypothesis, we first explored in vitro reduction in 
THTR-1 mediated thiamine uptake by genetic variants of THTR-1 associated with 
TRMA and several prescription drugs previously identified as inhibitors of THTR-1.  
Following these studies, we then screened drugs that are associated with DIMA to 
determine if any were able to inhibit THTR-1, and examined the potency of inhibition 
through IC50 experiments. Electronic medical record data were explored to evaluate the 
clinical impact of prescription drugs that were predicted to inhibit THTR-1 on blood 
levels of TPP. 
 
METHODS 	
Chemicals and Reagents 	
 [3H]‐Thiamine hydrochloride (catalog item ART 0710) was purchased from American 
Radiolabeled Chemicals Incorporation (St. Louis, MO, USA). The specific activity of [3H]‐
thiamine was 20 Ci/mmol.  Non-radiolabeled compounds were purchased from Sigma-Aldrich, 
Inc (USA), Selleck Chemicals (Houston, TX), VWR International, Inc (USA) and Thermo Fisher 
Scientific (USA). Cell culture supplies were purchased from the Cell Culture Facility (UCSF, 
California, USA) and Thermo Fisher Scientific (USA). 
Radiolabeled thiamine inhibition assays in HEK 293 Cells 
HEK 293 cells stably expressing THTR-1 were produced as previously described.14 These cells 
were plated in poly-D-lysine coated 24-well plates (200,000 cells/well); empty vector HEK 293 
cells were also plated as a negative control. Once cells reached 90% confluency, THTR-1 
expressing cells were transiently transfected with pcDNA5/FRT-SLC19A2 construct (500 ng per 
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well) using Lipofectamine® LTX with Plus™ reagent according to the manufacturer’s 
instructions (Life Technologies, Carlsbad, CA). Transfected cells were maintained in DMEM 
containing 10% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5 µg/ml puromycin 
(Thermo Fisher Scientific) at 37°C and 5% CO2 for 48 hours. 
Functional characterization of SLC19A2 variants causal for TRMA 	
There are at least 30 SLC19A2 mutations that are associated with TRMA3,15, but only the activity 
and/or expression of four TRMA variants has been characterized and published.  We selected 
three previously uncharacterized TRMA variants and characterized their activity using our in 
vitro assay (Figure 4.2). Variants in the pcDNA5/FRT-SLC19A2 plasmid were generated using 
site-directed mutagenesis (Genscript Inc); presence of each tested variant was confirmed using 
Sanger sequencing (MCLAB Inc).   
Selection of Drugs for Screening 	
Table 1 in the review article Drug Induced Megaloblastic Anemia,2 contains a list of prescription 
drugs and compounds associated with MA. Those compounds in addition to others belonging to 
listed drug classes (e.g. proton-pump inhibitors; a total of 63 compounds) were screened in 
triplicate at a 1 mM concentration to evaluate their potential to inhibit THTR-1 using the 
protocol depicted in Figure 4.3. 
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Figure 4.2 Functional characterization of SLC19A2 TRMA variants. 
Several SLC19A2 variants known to be causal for TRMA and never previously tested for activity 
were functionally characterized for transport activity using radiolabeled thiamine. Thiamine 
transport activities of the G172R was not statistically different from empty vector activity (p-
value = 0.5). At 200 µM, trimethoprim, a known inhibitor of SLC19A2 and drug associated with 
DIMA, reduced transport activity of wild type SLC19A2 to levels comparable to the activity of 
deleterious TRMA variants.   
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Figure 4.3 Common mechanisms of drug-induced megaloblastic anemia and THTR-1 
inhibitor drug screen workflow. 
Drugs associated with inducing megaloblastic anemia through various mechanisms (A) were 
obtained through commercial sources  Solutions containing each of the drugs  (1 mM) in buffer 
containing [3H] thiamine were exposed to HEK 293 cells expressing THTR-1 for 10 minutes. 
Drugs that inhibited 50% or more of THTR-1 mediated [3H] thiamine uptake were designated as 
inhibitors (10 total). Next, IC50 experiments were conducted on the THTR-1 inhibitors that did 
not have previously published IC50  information.   Last, we selected THTR-1 inhibitors for EHR 
analysis that were predicted to have systemic plasma levels or exposure within 10 fold of the 
estimated IC50 (B). 
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Methods Used for Screening THTR-1 for Inhibitors 	
Screening was performed using [3H]‐Thiamine (250 nM total of thiamine dissolved in Hank’s 
balanced salt solution (HBSS) (Figure 4.4A); wells were exposed for ten minutes (within linear 
range) to radiolabeled thiamine (positive control), radiolabeled thiamine plus 1 mM of 
amprolium (negative control) and radiolabeled thiamine plus 1mM of screened drug (3 replicates 
per drug). Next, IC50 assays were performed using a range of inhibitor concentrations (0.5 µM – 
1 mM, three replicates per concentration, Figure 4.4B). After ten minutes, the reaction was 
terminated by washing cells with ice-cold HBSS three times; cells were lysed for one hour using 
800 µl of lysis buffer (0.1 N NaOH and 0.1% SDS). The radioactivity (disintegrations per 
minute, DPM) of 450 µl of lysate was measured using a liquid scintillation counter machine and 
the DPM values were converted to picomoles of substrate. Total protein concentrations were 
determined using the bicinchoninic acid assay using 25 µl of lysate per well (ThermoFisher 
Scientific). Substrate uptake (in picomoles) was normalized by protein amount in each respective 
well.  
Calculating and/or identifying systemic plasma levels of THTR-1 inhibitors 	
Using clinical pharmacokinetic data from human studies16,17,18,19,20,21,22 and drug monograph 
databases (e.g. Micromedex, FDA) we obtained Cmax, fraction unbound (fu), maximum single 
dose and other parameters to determine if a single dose of inhibitor taken by patients will reach 
clinically relevant concentrations in the systemic circulation (i.e. if the R-value, the predicted 
ratio of the substrate’s AUC in the presence and absence of an inhibitor,   ≥ 1.1 ) (Table 4.1).23  
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Generation and analysis of physicochemical properties of THTR-1 drug screening 
library 	
Molecular structure files were obtained via ChemAxon Marvin Sketch (version 19.20.0). Based 
on the structures, 10 molecular descriptors (molecular weight, total polar surface area, logP, Van 
de Waals volume, formal charge, average molecular polarizability, hydrogen bond acceptor 
count, hydrogen bond donor count, number of rotatable bonds, and number of heavy atoms) were 
computed using ChemAxon Calculator (cxcalc; version 19.20.0). Statistical analysis and 
boxplots were generated using Graphpad Prism 8 (version 8.3.0). Boxplots display the following 
data distribution statistics: minimum, first quartile, median, third quartile, and maximum. 
Boxplot whiskers indicate the minimum and maximum values (Figure 4.5).  
Electronic medical record analysis of potent THTR-1 inhibitors 	
As previously mentioned, thiamine levels in the blood are normal in TRMA patients and  
Slc19a2( -/-) knockout mice.9 However, Xian and colleagues found that the concentration of TPP, 
the bioactive form of thiamine, was reduced in TRMA patients compared with normal patients.24 
Therefore, we used the UCSF electronic health record (EHR) database to evaluate TPP levels in 
the blood as a surrogate marker to track a potential effect of THTR-1 inhibition in hematopoietic 
cells and tissues by inhibitors identified in our screen and predicted to achieve plasma 
concentrations in the range of their THTR-1 IC50 values.  The UCSF Research Data Browser was 
used to search for patients who had a TPP lab (measured in whole blood by the UCSF Health 
Clinical Laboratories) test value reported, which gave us a total of 1,730 patients and 2,486 lab 
values. TPP levels reported as an inequality were changed to a numerical value (i.e. < 1.6nM = 
1.6nM).  
Patients were divided into two groups depending on their medication use. Patients prescribed 
erythromycin, which was predicted to achieve clinically relevant concentrations for inhibition of 
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THTR-1, were grouped into the “on” drug group. Search terms included “Erythromycin”, “Ery-
tab”, “Eryc”, “Erythrocin”, “Eryped”, and “E.E.S.” for erythromycin. Medication orders whose 
route of administration was topical, ophthalmic, and miscellaneous as well as orders without a 
medication order start date were excluded (Figure 4.6A).  The remaining patients (i.e. individuals 
who were never prescribed erythromycin) were grouped into the “off” drug group. Only patients 
with one TPP level were included in the “off” group, which reduced our sample size to 1278 
individuals for the erythromycin analysis (Figure 4.6A).  
 
Patients in the “on” group were further filtered based on their laboratory collection date relative 
to their first medication order start date. For erythromycin, TPP levels measured within 7 to 60 
days after their first medication order start date were included. A minimum of 7 days between 
medication start date and the TPP level was chosen to allow for an effect to be observed. For 
patients with more than one lab value, only the lab value closest to the first medication order start 
date was included. Lastly, patients were age- and sex-matched using the MatchIt package in R to 
be consistent in both the “on” and “off” groups which resulted in a final sample sizes of 4 
patients “on” drug and 200 patients “off” drug for the erythromycin analysis (Table 4.2) 
 
Despite omeprazole’s R-value being < 1.1, EHR analysis of omeprazole, which had the lowest 
IC50 of all investigated proton pump inhibitors, was conducted. Search terms included 
“Omeprazole” and “Prilosec”. Only patients with one TPP level were included in the omeprazole 
“off” group, which reduced the sample size to 893. These patients were age- and sex-matched 
using the MatchIt package in R, which resulted in 523 patients “on” drug and 523 patients “off” 
drug for the omeprazole analysis.  
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For patient population-specific analysis, patients were further sub-grouped based on a diagnosis 
of anemia. More specifically, anemia was defined as ICD10 Level 1 “Diseases of the blood and 
blood forming organs and certain disorders involving the immune mechanism (D50-D89)”, 
ICD10 Level 2 “Nutritional anemias (D50-D53)”, and ICD10 Level 3 “Folate deficiency”, 
“Other nutritional anemia”, and “Vitamin B12 anemia”. There were 3,767 patients with one or 
more of these diagnoses in the EHR database. The same workflow as described above was used 
for the patient population-specific analysis, but only lab values taken before or on date of 
diagnosis were included. Again, patients were age- and sex-matched using the MatchIt package 
in R, which resulted in 7 patients in the omeprazole “on” drug group and 28 patients in the 
omeprazole “off” drug group (Table 4.2). Based on the aforementioned criteria, the number of 
patients with a diagnosis of nutritional anemia and “on” erythromycin was too small to conduct 
analyses. Welch’s two sample t-test was performed to evaluate if there was a significant 
difference in lab values when comparing both groups; ggplot package in R (version 3.4.0) and 
GraphPad Prism 7 software was used to plot the data. 
 
RESULTS 	
THTR-1 variants causal for TRMA show significantly reduced thiamine uptake, 
which is comparable to thiamine uptake by reference THTR-1 exposed to certain 
prescription drugs. 	
Three previously uncharacterized variants, associated with TRMA, significantly reduced 
thiamine uptake in the cells (Figure 4.2).  In brief, HEK cells transfected with the TRMA 
variants had significantly reduced thiamine transport activity compared to cells transfected with 
wild-type THTR-1 (one-way ANOVA p-value < 0.0001).  TRMA transporter activity of one of 
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the three mutant transporters (i.e. G172R) was not significantly different from that of empty 
vector cells (Figure 4.2, p-value = 0.5) consistent with virtually no transport activity. We found 
that known inhibitors of THTR-1 transport (trimethoprim, amprolium) at 200 µM significantly 
reduced thiamine uptake by the reference THTR-1.  Notably, we observed that the reduction in 
thiamine uptake was not significantly different between the THTR-1 wild-type transporters 
exposed to the drugs compared to thiamine uptake by the mutant THTR-1 transporters (p-value ≥ 
0.1).  Though potency values need to be established, these results provide in vitro proof of 
concept that drugs may potentially phenocopy TRMA.  Based on these results we hypothesized 
that certain drugs that are associated with megaloblastic anemia may alter the absorption and 
distribution of thiamine in hematopoietic cells/tissues, by acting as inhibitors of THTR-1. 
 
A number of drugs known to cause MA were identified as inhibitors of THTR-1 in 
screening studies. 	
Over 60 drugs known to induce DIMA through various mechanisms were screened to identify if 
any were inhibitors of THTR-1 thiamine transport (Figure 4.3, Figure 4.4). Amprolium, a known 
inhibitor of THTR-1 14, was used as a negative control. Among the drugs screened, ten drugs 
were found to be substantial inhibitors of THTR-1 (≥ 50% reduction in THTR-1 transport). Of 
the ten inhibitors, six were novel (not previously known to inhibit the transporter) and included 
erythromycin, mycophenolate mofetil, omeprazole, pantoprazole, lansoprazole and chloroquine 
(Figure 4.4A); the other four compounds (fedratinib, amiloride, trimethoprim, amprolium) were 
previously shown to inhibit THTR-1.14,13,25  Leflunomide was found to be an intermediate 
inhibitor of THTR-1 (> 40%, but < 50% reduction in transport). Erythromycin is a tetracycline 
antibiotic used to treat a variety of infections. Mycophenolate mofetil is a drug used in solid-
organ transplant patients to prevent organ rejection. Omeprazole, pantoprazole and lansoprazole 
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are over-the-counter proton pump inhibitors commonly used to treat acid reflux disease. 
Chloroquine is an anti-malarial drug that is not commonly used in the U.S. Amiloride is a 
potassium-sparing diuretic often used in combination with other medications for blood pressure 
reduction and/or heart failure.  
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Figure 4.4 THTR-1 drug library screen and IC50 evaluation. 
In the screen, THTR-1 inhibitors were defined as compounds that inhibit at least 50% (dotted 
line) of thiamine uptake (A). Out of the 63 drugs screened, ten reached that threshold. 
Experiments were conducted using inhibitor concentrations from 0 to 1 mM. IC50 curves for 
erythromycin, omeprazole, amiloride, mycophenolate mofetil, cholorquine and pantroprazole 
were generated by fitting data to a nonlinear model (B).  Figures representative of 3 separate 
experiments except for pantoprazole (graph representative of one experiment).  
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Hydrophobicity associates with THTR-1 inhibition  	
Ten physicochemical properties of THTR-1 inhibitors and non-inhibitors were computed and 
compared: molecular weight, total polar surface area, logP, Van de Waals volume, formal 
charge, average molecular polarizability, hydrogen bond acceptor count, hydrogen bond donor 
count, number of rotatable bonds, and number of heavy atoms. The majority of molecular 
descriptors did not statistically differentiate THTR-1 inhibitors from non-inhibitors. The most 
statistically significant and informative physicochemical property was logP (Figure 4.5, student 
t-test p-value = 0.03) suggesting that THTR-1 inhibitors tend to be more hydrophobic than non-
inhibitors. 
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Figure 4.5 LogP associates with THTR-1 inhibition. 
Ten molecular descriptors were generated via Chemaxon and DataWarrior. Out of the ten 
descriptors, increased logP (hydrophobicity) was found to be the only significant descriptor to 
differentiate inhibitors from non-inhibitors (p-value = 0.03). H bond donor count demonstrated a 
trend towards SLC19A2 inhibitors having lower H-bond donors (p-value = 0.052). 
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Potency of inhibitors of THTR-1 ranged between 2.6 and above 400 µM 	
We evaluated the THTR-1 inhibition potency of the six novel inhibitors plus amiloride by 
conducting IC50 studies (Figure 4.4B). In contrast to fedratinib, amprolium and trimethoprim, 
previous IC50 studies on amiloride have not been published. Interestingly, amprolium was the 
most potent inhibitor of THTR-1 (Table 4.4).  Of the novel inhibitors that were identified in our 
screen, erythromycin was the most potent inhibitor of THTR-1 with an estimated IC50 of 20 µM. 
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Table 4.1 THTR-1 inhibitor potency (IC50). 
 
Experiments were conducted using inhibitor concentrations from 0 to 1 mM. IC50 curves were 
generated by fitting data to a nonlinear model; average IC50 estimates plus SEM were generated.     
* IC50 ± SD values were extracted from previously published data (PMID: 27803021). Data 
representative of 3 separate experiments except for pantoprazole (w = graph representative of one 
experiment).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prescription 
drug 
Mean IC50 
(µM) 
SEM  
(µM) 
SLC19A3 
inhibitor? 
Amiloride 69 17.7 Yes 
Chloroquine 301 33.4 No 
Erythromycin 21 8.24 No 
Mycophenolate 
mofetil 
145 
 
9.93 
 
No 
Omeprazole     207 
 
 
27.7 No 
wPantoprazole 429 -- No 
*Amprolium 2.6 0.93 Yes 
*Fedratinib 7.1 1.3 Yes 
*Trimethoprim 6.8 1.7 Yes 	
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Erythromycin predicted to inhibit THTR-1 thiamine transport in the systemic 
circulation 	
To compare the THTR-1 IC50 to the inhibitor’s systemic blood levels in humans, we collected 
and used the Cmax, fraction unbound (fu), and other parameters from clinical pharmacokinetic 
studies to calculate the R-value for all six THTR-1 inhibitors (Table 4.1).  Drugs found to have 
an R-value ≥ 1.1 were considered potentially clinically relevant THTR-1 inhibitors.23 After 
conducting R-value calculations, we found that erythromycin was the only THTR-1 inhibitor 
with an R-value ≥ 1.1. Essentially, a THTR-1 inhibitor with an R-value ≥ 1.1 is predicted to 
reach concentrations in the systemic circulation that reduce THTR-1 thiamine transport into 
hematopoietic progenitor cells, which are found in bone marrow.  
Erythromycin, designated as a potentially clinically relevant THTR-1 inhibitor, 
reduces thiamine pyrophosphate levels in red blood cells 	
To determine the clinical relevance of inhibitors we identified in the screen, we mined the 
electronic health records at the University of California, San Francisco to identify drug-induced 
decreases in TPP laboratory values. Specifically, we compared TPP levels in individuals 
prescribed erythromycin or omeprazole versus levels in individuals never prescribed either of 
these medications. Based on the inclusion/exclusion criteria described in the methods, we were 
able to classify patients as “on” drug (i.e. on omeprazole or erythromycin) or “off” drug. 
Population demographics, such as age and sex, were matched and comparable between both 
groups (Figure 4.6A, Table 4.2).   When examining data from all individuals in the EHR 
database, patients in the “on” group have significantly lower TPP levels compared to the “off” 
group for both omeprazole (student’s t-test, p-value: 0.0004; Figure 4.6B) and erythromycin 
(student’s t-test, p-value: 0.01). Figure 4.6 shows the results of our study and presents the flow of 
our analyses.   When we performed a patient-specific analysis and looked at individuals 
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diagnosed with folate, vitamin B12, and/or other nutritional anemia, although not significant, the 
trend still held where patients on omeprazole had lower TPP levels than patients not prescribed 
omeprazole (p-value: 0.35; n = 7 on drug, n = 28 off drug). There were no patients who met all 
the inclusion/exclusion criteria for the erythromycin patient-specific analysis. 
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Figure 4.6 Average thiamine pyrophosphate levels in the general population of patients 
on or off omeprazole.  
Patients with or without a diagnosis of megaloblastic anemia who had one thiamine 
pyrophosphate level were extracted from the UCSF EHR (A). The thiamine pyrophosphate 
levels of patients on an inhibitor (omeprazole or erythromycin) versus those not on an inhibitor 
were compared. The average TPP levels for patients on omeprazole was significantly lower (152 
nM, N=510) than that of the TPP levels of patients not taking omeprazole (201 nM, N=510) 
(students t-test, p-value = 0.0004) (B). The average TPP levels for patients on erythromycin was 
lower (137 nM) than that of the TPP levels of patients not taking omeprazole (186 nM) (p-value 
= 0.0016) 
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Table 4.2 Average age and gender in drug-exposed versus unexposed groups. 
Omeprazole analysis 
 On Off 
Gender 
     % Female 71 71 
     % Male 29 29 
Age 
     Mean  48.8 49.3 
Erythromycin analysis 
 On Off 
Gender 
     % Female 50 54 
     % Male 50 46 
Age 
     Mean 32.3 33.8 
Omeprazole - Megaloblastic Anemia analysis 
 On Off 
Gender 
     % Female 57 61 
     % Male 43 39 
Age 
     Mean 55.1 51.8 
Patients were age- and sex-matched using the MatchIt package in R to be consistent in both the 
“on” and “off” groups. The average age and gender percentage for each analysis was not 
statistically different between the “on” and “off” groups (Welch’s two sample t-test, p-value > 
0.5)  
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Discussion and Conclusions 	
Comprehensive THTR-1 inhibitor screens and kinetic evaluations of drugs associated with 
DIMA were conducted in this study.  Furthermore, EHR data of patients who were or were not 
exposed to THTR-1 inhibitors predicted to reach plasma levels that may inhibit the transporter 
were extracted and analyzed. The study led to five findings:  
First our screen of drugs that inhibit THTR-1 indicates that a limited number of prescription 
drugs may inhibit the transporter and suggests the possibility of THTR-1 drug-vitamin 
interactions.   Many prescription library inhibitor screens have been conducted for drug 
transporters (i.e. OATPs, OCTs, MATEs), which modulate the disposition of many prescription 
drugs. 26,27,28,29 The FDA recommends that any new investigational small molecule be 
tested/screened in vitro for significant inhibition of intestinal, hepatic and renal drug transporters 
such as organic anion transporting polypeptides (OATPs), organic cation transporter (OCTs) and 
multi-antimicrobial extrusion protein (MATEs).23 If the R-value for an OATP1B1/1B3 inhibitor 
≥ 1.1, the inhibitor is predicted to affect the substrate disposition in-vivo and a clinical drug-drug 
interaction trial may be warranted.23 However, to date, the FDA has not developed 
recommendations for testing/screening small molecules as inhibitors of critical vitamin 
transporters to assess the liability of new drugs to cause drug-vitamin interactions. Though our 
study represents the largest prescription drug library screen for inhibitors of THTR-1, the screen 
was still limited.  Notably, 60 drugs represent less than 10% of approved oral drugs suggesting 
that larger screens may be warranted to identify prescription drug inhibitors of THTR-1 and 
other nutrient transporters.  Such screens should be guided by clinical information. For example, 
if other detrimental drug-vitamin interactions (e.g. fedratinib) are exposed,30, 31 additional 
prescription drug library screens focused on critical vitamin transporters should be conducted to 
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identify other potential drug-vitamin interactions and inform clinicians and patients regarding 
risk for drug-vitamin interactions.   
 
Our second finding is that inhibitors of THTR-1 have greater logP values in comparison to non-
inhibitors (Figure 4.5). Greater logP values have been associated with inhibitors of other 
transporters (e.g., OCT1 and MATE1), 27 therefore a high logP value is likely a general property 
of many transporter inhibitors.  As our study was limited to 60 drugs, future computational 
analysis together with high-throughput screens with larger libraries are needed to identify 
molecular/chemical signatures that are specific to THTR-1 inhibitors; these signatures can be 
used to pre-screen new molecular entities or other prescription drugs before use in populations 
vulnerable to MA and DIMA (e.g. elderly).  
 
Our third finding is that several prescription drugs associated with MA inhibit THTR-1 with IC50 
values of 200 µM or lower (i.e., trimethoprim, fedratinib, amiloride, mycophenolate mofetil, 
erythromycin, omeprazole).  At least four (trimethoprim, mycophenolate mofetil, erythromycin, 
omeprazole) of the six drugs have been thought to cause MA through other validated 
mechanisms (e.g., absorptive inhibition of folic acid or vitamin B12).2   Though further studies 
are clearly needed, it is possible that inhibition of THTR-1 represents an additional mechanism 
for inducing MA for some of these drugs.     
 
Fourth, our study demonstrates that erythromycin is a potent THTR-1 inhibitor that may inhibit 
the transporter clinically, that is, at concentrations associated with therapeutic doses of the drugs.  
In further studies, we found that erythromycin and omeprazole are associated with significantly 
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reduced blood levels of TPP, the bioactive form of thiamine, using EHR data.  Most small 
molecule FDA approved drugs have systemic blood concentrations within the nanomolar to 
micromolar range or less.32 We determined through examination of pharmacokinetic data that 
erythromycin’s R-value for THTR-1 ≥1.1, suggesting that it may inhibit the transporter at 
therapeutic doses. Erythromycin is a macrolide antibiotic that was commonly used in the past to 
treat skin/soft tissue and blood infections but was associated with many drug-drug interactions 
and adverse effects, many of which were unexplained.  Of note, is that hearing loss is a known 
adverse effect of erythromycin. Our data showing that erythromycin may inhibit THTR-1 
suggest a potential mechanism for this adverse effect. That is, TRMA caused by genetic 
mutations in SLC19A2 is generally characterized by hearing loss.  Though speculative, inhibition 
of THTR-1 may be a mechanism of erythromycin induced hearing loss.  However today, other 
macrolides with fewer drug-drug interactions and adverse effects are commonly used in place of 
erythromycin. Additionally, we found the R-value for omeprazole was < 1.1, which means it is 
not predicted to inhibit THTR-1 in-vivo. This result was based on a range of Cmax levels found in 
patients who took a single dose of omeprazole between 40-90mg.33 Omeprazole is a first-in-class 
proton pump inhibitor used to treat symptoms of gastrointestinal reflux disease (GERD) or 
gastrointestinal ulcers. Its estimated that over 70 million prescriptions for omeprazole were 
generated in 2016. 34 Importantly, the drug is chronically used with an average duration of 
treatment of 3 months with some patients on omeprazole for years.35,36 Notably, a subset patients 
treated with omeprazole have hypersecretory disorders (e.g. Zollinger –Ellison syndrome) that 
require very high doses of omeprazole (i.e. 120mg three times a day for a total daily dose of 
360mg). It is possible that the initial Cmax and steady state Cmax values in patients treated with 
high dose omeprazole could be much higher than those treated with normal doses, especially if 
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these patients are CYP2C19 poor metabolizers. Thus, patients chronically receiving 
erythromycin or large doses of omeprazole with CYP2C19 inhibition may have sufficiently high 
concentrations over extended periods of time to inhibit THTR-1 in hematopoietic cells and 
potentially reduce the levels of TPP.  Lower TPP levels in blood cells may result in reduced 
DNA synthesis and lead to increased susceptibility to MA. Our EHR data analysis supports this 
possibility (Figure 4.6). 
 
Finally, our data show that erythromycin and omeprazole are associated with significantly lower 
levels of TPP, the bioactive form of thiamine, in UCSF medical center patients. EHR data are 
notoriously noisy; therefore, selected patients in the “on” and “off” medication groups were age 
and sex-matched and the reduction in TPP levels kept its significance.  Even in our subgroup 
analysis (i.e. megaloblastic anemia) the trend of lower TPP levels in patients on omeprazole still 
held. The reduction of TPP levels in patients exposed to erythromycin or omeprazole seems to 
“phenocopy” the effects of genetic THTR-1 deficiency on TPP levels in TRMA patients.24 
Additionally, we searched the EHR for patients who were exposed to either erythromycin or 
omeprazole and had vitamin B12, folic acid, RBC and TPP levels measured before their diagnosis 
of MA. Out of thousands of patients diagnosed with MA, only two patients on omeprazole had 
all three levels obtained before diagnosis. One of the patients was diagnosed with “Other 
nutritional anemia” and had normal vitamin B12 and folic acid levels in RBCs, but low TPP 
levels (data not shown). This result suggests that despite the clear ability of thiamine deficiency 
to induce MA, TPP is not routinely ordered in patients suspected of having DIMA or MA; 
therefore the incidence of DIMA caused by THTR-1 inhibitors may be significantly under 
reported. Though further studies are clearly needed, our study highlights an underrated etiology 
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of megaloblastic anemia (thiamine deficiency) and suggests an additional mechanism of DIMA, 
THTR-1 inhibition.  
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Chapter 5: Conclusions and Perspective 
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This dissertation underscores the importance of mechanistic studies to understand the biological 
mechanisms underlying human disease, variation in drug response and drug-induced toxicities.1,2  
A large part of the research presented here centered on studies designed to discover rare genetic 
variants in SLC2A2 that underlie inter-individual variation in metformin response (Chapter 2) 
and the characterization of rare variants in SLC2A2 that have been associated with FBS (Chapter 
3).   Further, it examined the role of SLC19A2 in drug-induced megaloblastic anemia.   Below I 
summarize each of the chapters and provide some insights into limitations and future studies.   
 
In Chapter 2, we used next-generation sequencing to identify genetic variants in SLC2A2 that 
associate with extreme non-response. The study was based on the fact that common variants in 
SLC2A2 associate with variation in response to the anti-diabetic drug metformin; therefore rare 
variants in the gene may have larger effects and associate with extreme non-response to the drug.   
One of the major issues in pharmacogenetic studies, in general, is power.4 Pharmacogenetic 
GWAS usually contain smaller cohorts compared with disease GWAS due to problems in 
obtaining well-defined, drug response phenotypes and prescription information, which is often 
not available in electronic medical records.  For pharmacogenomic sequencing association 
studies, power is not only affected by the lack of prescription data and a well-defined phenotype, 
but by the type and cost of sequencing that can be performed based on the available budget. 
Additionally, the total sample size of the cohort not only affects the power to find a statistical 
association but the power to detect rare or less common variants.  
In Chapter 2, one of the greatest difficulties was choosing the type of next-generation sequencing 
method to select (i.e. whole genome, whole exome, target region) due to budget constraints. 
Whole genome or whole exome method would provide the data needed to conduct a truly 
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genome-wide evaluation of the impact of all genes and their rare/less common variants on 
metformin response. However, whole exome sequencing, which is cheaper than whole genome, 
on average cost a little under $1000 per sample;5 with approximately one-thousand samples, the 
average cost of whole exome sequencing the entire METRO cohort would have been about 
$1,000,000 and above our budget. Therefore, we chose to move forward with our full sample 
size while reducing the size of the region to be sequenced. We sequenced extreme responders 
and non-responders in the METRO cohort using targeting sequencing of SLC2A2. Despite losing 
genome-wide breadth, the large sample size sequenced will increase the number of rare and less 
common variants we can detect in SLC2A2 and therefore statistically analyze. 
 
In the study conducted in Chapter 3, which focused on mutations in SLC2A2 that are causal for 
FBS, we came to two major conclusions. First, p.Leu153_Ile154del mutant GLUT2 had residual 
transport activity, which may explain the mild phenotype of FBS exhibited in the two patients 
who are compound heterozygous for p.Leu153_Ile154del (which has residual transport activity, 
about 5% of wild-type activity) and p.Pro417Arg (which has no transport activity). The 
significant reduction in disease severity despite a small increase in GLUT2 transport hints at the 
therapeutic possibilities of “slight” or “residual” GLUT2 activation, and also to a “functional 
threshold” required to initiate disease.  Deleterious variants in different SLC transporters cause a 
range of autosomal, recessive diseases (i.e. SLC2A2/Fanconi-Bickel syndrome, 
SLC22A5/Carnitine Transporter Deficiency (CTD) syndrome, SLC19A2/Thiamine-responsive 
megaloblastic anemia (TRMA)). All SLC2A2 FBS variants functionally characterized thus far 
completely abolish GLUT2 transport except for one (p.Leu153_Ile154del).3 But several 
SLC22A5 missense variants causal for CTD still retain residual or partial transport activity, 
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despite the presence of clinically significant carnitine deficiency.6 Therefore, the efficacy of 
treatments for these diseases will likely vary based whether the treatment can increase transport 
activity of the substrate(s) above the “functional threshold”.  
 
Our second conclusion was that 45% of GLUT2 FBS mutant transporters were not expressed or 
negligibly expressed on the plasma membrane. This conclusion demonstrates that significant 
portion of rare, deleterious variants in genes that encode for membrane transporters cause disease 
by preventing the trafficking to and/or expression of that membrane transporter on the plasma 
membrane. Other GLUT transporters (e.g. GLUT9) have sequence motifs that target their 
expression to specific parts of the plasma membrane.7 Disruption of those motif sequences 
affects membrane trafficking. However, FBS variants not expressed on the plasma membrane are 
not clustered in one specific part of SLC2A2 but are located throughout its sequence.3 A few of 
those FBS variants exhibit some partial or “leaky” expression on the membrane, but most show 
no expression at all. Creation of a detailed map of GLUT2 folding and trafficking from nascent 
single-strand protein to folded, membrane-embedded transporter would help illuminate the 
mechanisms by which these variants prevent or hinder plasma membrane expression.  
Furthermore, these results suggest that either pharmacochaperones and/or allosteric activators 
(depending on the mechanism underlying the functional loss of the transporter) that stimulate the 
transport activity of FBS mutant transporters, even with a slight gain in function (as noted for the 
individuals harboring the p.Leu153_Ile154del of GLUT2) may provide therapeutic benefit.   
 
Unfortunately, this dissertation also reveals that popular functional protein prediction algorithms 
(e.g. POLYPHEN, SIFT) have reduced accuracy when predicting the function of mutant 
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membrane transporters. Data from these protein prediction algorithms are often used, instead of 
functional characterization, to stratify or weigh variants in a statistical association analysis, 
especially for rare variant association analyses.  Variants predicted to be destructive or 
dysfunctional to protein function are given higher weight in the association analyses. Similarly, 
after association analyses are conducted, protein prediction algorithms are used to triage 
associated variants and determine which variants alter protein function and are therefore likely to 
be a causal variant.8 Out of twenty-one SLC2A2 variants (15 FBS, six less common) functionally 
characterized, 5 were incorrectly predicted by POLYPHEN (24%). Three out of three SLC19A2 
variants functionally characterized were correctly predicted by POLYPHEN.  
 
Finally, the latter portion of this dissertation evaluated the potential of drug-vitamin interactions 
to phenocopy signs and symptoms of corresponding genetic diseases. The study of drug-vitamin 
interactions is a relatively small field compared to drug-drug interaction studies. But the delayed 
FDA-approval of Janus kinase 2 inhibitor, fedratinib, due to the development of Wernicke’s 
encephalopathy, highlighted the significant clinical toxicities that can occur from drug-vitamin 
interactions.9 The study in Chapter 4 identified at least one prescription drug that may potentially 
inhibit THTR-1 transporters at physiological concentrations (erythromycin).   Reduced blood 
levels of thiamine pyrophosphate were identified in patients prescribed either erythromycin and 
omeprazole, using real-world data from the electronic health record.  Collectively, the studies 
suggested a novel mechanism of drug-induced megaloblastic anemia that resembles thiamine-
responsive megaloblastic anemia (TRMA), a Mendelian disease caused by inactivation of 
THTR-1 transporters. Prospective, controlled in-vivo human trials are needed to confirm the 
	 128	
effect of erythromycin and omeprazole on thiamine pyrophosphate blood levels and risk of 
megaloblastic anemia.  
 
In summary, this dissertation conducts an in-depth investigation of SLC2A2 variation and its 
influence on inter-individual differences in metformin response and FBS disease severity.   It 
also suggests the potential of prescription medications to cause adverse reactions through chronic 
THTR-1 (thiamine transporter) inhibition. Notably, we identified the first FBS-associated 
mutation that still retains residual transport activity (p.Leu153_Ile154del) in patients that exhibit 
a mild form of FBS.3 And we identified two novel inhibitors of THTR-1 (omeprazole, 
erythromycin) that associate with reduced levels of thiamine pyrophosphate. These findings 
expand our knowledge regarding the genotype-to-phenotype relationship of FBS and highlight 
the importance of functional characterization and annotation of membrane transporters. While 
additional replication cohorts of metformin response would help to increase power and confirm 
rare-variant associations, in-depth mechanistic studies investigating the relationship between 
SLC2A2 and metformin response will offer further biological insights into the mechanisms of 
metformin action and inform its expanded use in diverse patient populations. 
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